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Paired tumour and blood samples from 100 patients with primary
breast cancer, and 100 placental controls have been collected and in
many instances lymphoblastoid cell lines have been established. DNA
has been extracted from all these sources. Blood samples have been
collected from all living members of a large family with a high
incidence of breast cancer; DNA has been extracted and
lymphoblastoid cell lines established.
The frequencies of the common and rare BamHI Harvey Ras alleles
in breast cancer patients have been determined; there is no signifi¬
cant difference in their distribution when compared to controls from
the same general population.
Allelic loss at the Harvey Ras locus was found in (chromosome
llpl5.5) 13 out of 65 informative tumours and this loss is related to
several clinico-pathoological indices, such as tumour size and
oestrogen receptor status.
Five other regions on lip have been fully examined in a panel of
19 tumour/lymphoblastoid cell line pairs. The data indicated that
complex breakage and recombination events had occurred in at least a
proportion of tumours, thus precluding identification of a shortest
area of consistent deletion.
Several other areas of the genome have been studied to confirm
that a high frequency of allelic loss is restricted to defined
chromosomal regions.
Allelic loss of the locus defined by the minisatellite probe YNZ
22 on 17p 13.3 has been identified in 23 out of 38 informative
tumours (61%). This loss is not related to any clinico-pathological
parameters examined.
Taq 1 YNZ 22 genotypes for all members of a large kindred,
containing 7 cases of breast cancer were identified. These geno¬
types were significantly linked to the trait of breast cancer sus¬
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1 GENETICS OF BREAST CANCER
Historical Perspective
The identification of several "cancer-ridden" families
stimulated a number of prominent 18th Century physicians to consider
whether "there were any proofs of cancer being an hereditary
disease?" (Shimkin 1957).
The remarkable pedigree of "Madam Z" was reported by the French
surgeon, Paul Broca, in 1866. It is believed that the family
described may indeed have been his wife's. He ascertained the cause
of death in 38 individuals through 5 generations. Ten out of 24
women in that family died of breast cancer, and several more
individuals died of other malignancies. Both Broca and his con¬
temporary, Sir James Paget (Paget 1853; Lane-Clayton 1926) expressed
concern that multiple instances of such a common disease might appear
in a small number of families by coincidence, but using the available
data on cancer mortality rates in the normal population, they con¬
cluded that a tendency to develop breast cancer could indeed be
inherited.
Advances in statistics, epidemiology and genetics allowed more
rigorous examination of these initial observations in the first half
of the 20th Century. Several groups attempted to compare the
mortality from breast cancer in a population of patients with one or
more affected relatives and in a normal control population (Jacobson
1946; Woolf 1955; Anderson et al 1958; Kelsey 1978 and Lynch
1981). These studies highlighted the importance of pathological
verification of malignancy, of assessing the incidence of malig¬
nancies other than breast cancer and of using large numbers of
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families plus reliable data on cancer incidence and mortality in the
general population. Overall they showed that there was a two-fold
increase in breast cancer incidence in first degree female relatives
of breast cancer patients. Under-reporting of disease by control
subjects was recognised as a significant problem which remains hard
to surmount.
Segregation Analysis
In some classical "genetic disorders", inspection of the
pedigrees of a few affected families will reveal the mode of trans¬
mission (autosomal or sex-linked, dominant or recessive). However,
in the vast majority of diseases, where the genetic component is less
clearcut, a more comprehensive statistical analysis is required.
Segregation analysis is the name given to the process of determining
the probable mode of transmission of a trait, from an observed
distribution of phenotypes in a pedigree or a number of pedigrees.
The procedure involves calculating how well the observed dis¬
tribution of phenotypes fits various hypotheses and can thus estab¬
lish that some of these hypotheses are very unlikely although it may
not prove conclusively that a trait is transmitted genetically. The
larger the families examined, the more affected individuals in each
family and the larger the total number of families, the better will
be the data and the more secure the final conclusions.
Several statistical advances, such as maximum likelihood
scoring, the concept of multi-factorial inheritance, the "mixed
model" and a sampling correction to allow for the manner in which the
pedigrees have been ascertained and relatives added (Morton 1955,
1983; Falconer 1965, 1967; Morton and Maclean 1974; Elston and
Sobel 1979; Lalouel and Morton 1981) have all been incorporated into
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a segregation analysis, performed on 200 Danish families with breast
cancer (Williams and Anderson 1984).
The observed distribution of breast cancer in these families was
compatible with transmission of a single autosomal gene with dominant
expression, the frequency of the abnormal (disease) allele being 0.7%
and the penetrance varying with age. According to that model, by
age 80, a female heterozygous for the abnormal allele would have a
57% chance of developing breast cancer. For cancer presenting
before age 30, 88% of affected females would be carriers of the
disease gene whereas for the total population, accepting all cases
presenting up to age 80, only 13% of affected females would carry the
gene.
Several similar analyses have been performed on another large
breast cancer family and all agree that an autosomal dominant gene
with incomplete penetrance is the most likely mode of transmission
(Gardner and Stephens 1950; Hill et al 1978; Gardner 1980).
Hereditary Breast Cancer
On the basis of many published studies (Jacobsen 1946; Woolf
1955; Anderson et al 1958 and Kelsey 1979) it has been suggested
that breast cancer can be divided into two sub-groups, familial and
sporadic.
H T Lynch and colleagues (Lynch et al 1984) operationally
defined "familial" breast cancer as the occurrence of two or more
breast cancer affected relatives within the modified nuclear pedigree
(inclusive of the proband). Families in which one or more of the
following cardinal features were present were defined as having
hereditary breast cancer.
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1 Significantly early age of onset
2 Excess of bilaterality
3 Vertical transmission (mother-to-daughter)
4 Impaired survival when compared with sporadic forms
5 Excess of multiple primaries at various sites.
Applying these criteria, they estimated that 18% of breast
cancer is familial, 5% of all breast cancer is hereditary and 11.5%
of patients with breast cancer, diagnosed before the age of 50, have
a hereditary form of the disease.
Anderson (1971, 1972) adopted a somewhat different approach,
dividing his cases into sub-groups and identifying the groups in
which the risk was increased beyond the two or three-fold level
observed in the earlier studies (Jacobsen 1946; Kelsey 1979). The
relative risk to first degree female relatives of patients with pre¬
menopausal breast cancer was 3.1, while no increase in risk was
observed among relatives of post-menopausal patients. If the
patient had bilateral breast cancer, the risk to first degree female
relatives was increased five-fold. If both conditions applied (ie,
the patient was pre-menopausal and had bilateral disease), the risk
to first degree relatives was increased nine-fold. Furthermore, the
relatives of patients with bilateral disease were at a nine times
greater risk of developing bilateral disease themselves as compared
to relatives of patients with unilateral disease.
The importance of age and of bilaterality have been confirmed in
other studies (Bain et al 1980; Chaudray et al 1985) and so, despite
one dissenting report from a large Swedish study in which the effects
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of family history, age of onset and bilaterality were rather weak
(Adami et al 1981), we are now in a position to identify a group of
women who are at significantly higher risk of developing breast
cancer than the general population, who are likely to be more aware
of (and concerned about) their susceptibility to the disease (Kelly
1980), and who therefore require detailed and accurate counselling
about that risk (Ottman et al 1983).
Several families have been reported in which breast cancer is
associated with other primary neoplasms, such as endometrial
carcinoma, (Lynch et al 1967), colonic carcinoma (Lynch et al 1973),
ovarian carcinoma (Lynch et al 1978a), and leukaemia, brain tumours
and sarcoma (Lynch et al 1978b). Multiple primaries can affect
single individuals and/or different tumours occur among family
members. These rare families may carry a different genetic lesion,
influencing cell behaviour in a more fundamental way, than that
occurring in families developing only breast cancer, but one
advantage in studying them is that such a defect might be easier to
detect if only because, with the opportunity for the gene to be
expressed in a variety of forms, penetrance is expected to be
relatively high.
The identification and study of both types of family is
important in attempting to identify a gene for susceptibility to
breast cancer and I shall return in a later section to consider the
most informative method of analysing these families.
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2 TUMOUR SUPPRESSOR GENES
The Two Hit Hypothesis
In 1971 A G Knudson (1971) published a hypothesis which provided
a theoretical basis linking the molecular mechanisms underlying
hereditary and sporadic cancers. He proposed that development of
the malignant phenotype required two separate "hits", or mutations in
sporadic tumours, but in hereditary tumours, the first "hit" is
inherited in the germ line, and so only one somatic mutation is
required. This hypothesis was based on a study of the childhood
ocular tumour, retinoblastoma.
This tumour is usually recognised before 5 years of age, and has
had a reasonably high cure rate for most of this century, permitting
the early observation that some survivors produced affected off¬
spring. In patients who have had bilateral tumours, about 50% of
\
their offspring are affected and 50% are unaffected, suggesting such
patients bear a "retinoblastoma mutation" which is transmitted in
dominant Mendelian fashion. Most patients with a unilateral tumour,
produce unaffected offspring, although 10-15% are affected. Most of
the latter develop bilateral tumours.
Knudson calculated that 60-75% of gene carriers develop
bilateral tumours, 25-40% develop unilateral tumours and between 1
and 10% do not develop the disease, although the trait is transmitted
to their offspring, suggesting the number of tumours developing in a
gene carrier fits a Poisson distribution. Pathological data
confirmed that gene carriers develop a mean number of 3-4 tumours.
Thirty-five to 40% of total retinoblastoma cases appear to be
"hereditary" and the incidence of these is 5 per 100,000 children.
Therefore the probability that a non-carrier will develop the disease
7
is 3 per 100,000. As the mean number of tumours per gene-carrier is
3, the risk for one tumour in gene-carriers relative to non-carriers
is 100,000:1 (Knudson 1978).
There are 10^ cells in the normal retina, so even in gene-
carriers, it is a very rare cell that becomes malignant, strongly
suggesting a second event is involved, following a Poisson distri¬
bution, and therefore likely to be random. Knudson calculated that
the frequency of this second "hit" was roughly equal to the frequency
of the first "hit" acquired in non-hereditary tumours and likely to
be a mutational event (Knudson 1971). This mathematical treatment
could not of course cast light on whether the second event in non-
hereditary tumours is the same as the first event in hereditary
tumours.
Localisation of the Retinoblastoma Gene
In some families with retinoblastoma, the disease is inherited
along with a visible deletion in the long arm (q) of one of the
chromosome 13 pair. These deletions are of variable length but all
include one particular band - 13q 14 (Knudson 1976; Yunis 1978).
The gene coding for the polymorphic enzyme esterase D, was shown
to be located at 13q 14 (Chen 1974; Ward 1984). The serum levels
of esterase D are reduced to 50% of normal in those with a visible
deletion, (and in several without visible deletions), suggesting that
even submicroscopic deletions include both the esterase D gene and
the retinoblastoma gene (Sparkes 1980). There are two allelic forms
of esterase D in the normal population, EsD 1 and EsD 2, and in
informative pedigrees one allele segregated with the disease.
(Connolly 1983; Sparkes 1983). This is good evidence that the same
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genetic site i.e. 13q 14 is involved in all hereditary forms of
retinoblastoma, irrespective of whether a visible deletion is present
or not.
Cytogenetic analysis was possible in about 20% of non-hereditary
tumours, and all showed absence of, or a deletion on, one of the No
13 chromosomes - all involving 13q 14 (Balaban 1982; Benedict 1983a;
Gardner 1982), suggesting that the same locus is involved in both
hereditary and non-hereditary forms.
Expression of the Retinoblastoma Gene
Three classes of events could lead to loss of the normal allele
at the retinoblastoma locus (Knudson 1978).
1 Submicroscopic mutation (designated 13qr^, the normal allele
being 13q+.
2 Deletion (13q~).
3 Chromosomal loss (13-).
If expression of the retinoblastoma gene is recessive, and the second
event involves the development of homozygosity to allow expression,
then 6 tumour genotypes can be imagined, 13qr^/13qr^, 13qr^/13q~,
13qrk/13", 13q~/13q~, 13q~/13~, 13_/13~. The last genotype would
probably be fatal as would the fourth and fifth if enough genes were
lost; however, the first three genotypes might be compatible with
tumour cell survival.
The first event, a mutation, is to 13qrk, and the second event
is then another mutation in the first case, a deletion in the second,
and complete chromosomal loss by non-disjunction in the third. The
first genotype could also be caused by somatic recombination, whereby
a heterozygous cell, 13qr^/13q+, produces two homozygous cells, one
normal, 13q+/13q+, and the other tumourigenic, 13qr^/13qr^.
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The first evidence that the retinoblastoma gene was rececessive
came from studying a hereditary case with no visible deletion in the
leucocytes, in which the serum esterase D level was 50% of normal,
suggesting a submicroscopic deletion of the retinoblastoma and
esterase D genes in one copy of chromosome 13. The tumour cells had
only one copy of chromosome 13, and had no esterase D activity,
suggesting that the tumour genotype was therefore 13q~/13~, and the
tumour had lost the normal chromosome 13 (Benedict 1983b; Murphree
1984).
The identification of several highly polymorphic DNA segments on
the long arm of chromosome 13 (Cavenee 1983, 1985), has provided
further evidence that the retinoblastoma gene is recessive. Some
tumours in heterozygous individuals have lost one allele, indicating
that a portion of one copy of chromosome 13 has been lost, i.e.
„ i
13qrD/13q , while in some tumours all heterozygous markers have been
reduced to apparent homozygosity (Dryja 1984), indicating probable
loss of one chromosome and the acquisition of a second copy of the
other chromosome by non-disjunction. A few tumours show no loss of
heterozygosity, with no esterase D deficiency and are presumably
13qrb/13qrk, while others show no loss of heterozygosity but
reduction of esterase D activity, suggesting a submicroscopic
deletion involving the retinoblastoma gene and the esterase D gene,
but none of the other markers (Dryja 1984).
These findings in retinoblastoma indicate that the retino¬
blastoma gene is recessive at a cellular level, and that a second
event is required to allow its expression. In hereditary retino¬
blastoma, every one of the 10^ cells in the retina have inherited the
first "hit" and so the chances of at least one cell acquiring the
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second "hit" are so high that the trait (i.e. development of at least
one tumour) appears to be transmitted as a Mendelian dominant
characteristic. In some ways the term "hereditary retinoblastoma"
is misleading, as it is the predisposition to develop a tumour which
is inherited (Knudson 1985).
The normal copy of the retinoblastoma gene (13q+) appears to
suppress the activity of the mutated gene (13qr^) and therefore acts
as a tumour suppressor gene. Similar experimental findings have
been reported in Wilm's tumour (nephroblastoma), hepatoblastoma, and
rhabdomyosarcoma (Koufos 1984, 1985; Orkin 1984; Reeve 1984;
Fearon 1984 and Rogler 1985), but the gene implicated in these
tumours lies on the short arm of chromosome 11 (lip). It is likely
that a number of different tumour suppressor genes are scattered
throughout the genome (Lancet 1988). It is therefore logical to
examine DNA from both hereditary and non-hereditary tumours to
attempt to identify sequences which are consistently lost in the
tumour tissue, as these sequences might well be new tumour suppressor
genes.
Another term coined for tumour suppressor genes is anti-
oncogenes (Knudson 1985; Green 1985; Friend 1988). They appear to
act in a recessive fashion at the cellular level in contra¬
distinction to the larger number of oncogenes identified, which act
in a dominant fashion at the cellular level, and which will be




The Identification of DNA sequences capable of producing a
malignant cellular phenotype in a dominant fashion, i.e. without loss
of the normal homologue, has resulted from three main experimental
approaches; investigation of tumour-producing viruses, transfection
of human tumorigenic DNA into immortalised cell lines and visual
chromosome analysis.
The first clues came from an understanding of the structures of
oncogenic retroviruses. The genetic material of these viruses is
RNA but once inside an infected cell, the RNA is copied into DNA
which then integrates into the chromosomal DNA of the host. Later
it may be transcribed and translated by the host cell's replication
system, unleashing a second generation of virus. These viruses can
be divided into two broad groups, depending on the rapidity with
which they produce tumours. Slowly transforming viruses contain
three genes; "gag", which codes for specific antigens mainly located
at the core of the virus, "pol", which codes for reverse tran¬
scriptase and "env", which codes for the envelope protein. The
acutely transforming viruses contain another gene termed an
"oncogene", specific to each virus and directly responsible for
induction of malignancy in infected cells (Bister 1982; Yoshinaka
1985).
Analysis of the nucleotide sequences of retroviral oncogenes
revealed that they were very similar to sequences ("proto-oncogenes")
found in the genome of higher organisms, including man (Stehelin
1976; Bishop 1981). It is virtually certain that the acutely
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transforming viruses arose by recombination between non-oncogenic or
slowly transforming viruses and the cellular proto-oncogenes. At
least 22 viral oncogenes have been identified so far (Bishop 1983).
The second productive experimental approach has been direct DNA
transfection/transformation. DNA from human tumours or tumour cell
lines is precipitated onto the surface of the cells in culture using
calcium phosphate, or by electroporation (Steel 1984). A small
proportion of the DNA enters the cells and an even smaller fraction
becomes integrated into the genome in a random fashion. Cells
"transformed" by this technique exhibit uncontrolled proliferation
and form distinct colonies on agar plates, which can be isolated and
cloned up (Shih 1982). When injected into immunologically-
compromised animals, such as nude or neonatally thymectomised and
irradiated mice, these transformed cells produce tumours, suggesting
that a segment of DNA responsible for producing the original human
tumour, has been integrated into the cell's genome (Krontiris 1981;
Porteous 1986). These oncogenes can then be identified by comparing
extracted DNA from the transformed cells and from the original cell
line.
Eleven new cellular oncogenes, without viral counterparts have
been identified by this technique (Bishop 1983). Among the few
oncogenes identified by both transfection and viral studies are
members of the ras gene family which will be considered more fully
later.
One of the main limitations of DNA transfection studies is that
the target cells used, usually 3T3 or C127 mouse fibroblasts, though
subject to some normal growth controls, are immortal. They
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therefore represent an intermediate stage between the normal and
full-blown malignant states. Co-transfection of at least two
different oncogenes, for example, Ha-ras and C-Myc is generally
required to achieve tumorigenic transformation of normal cells (Land
1983).
The molecular mechanisms underlying the process of immortalising
a normal cell are very poorly understood, but it is likely that
transfection studies are capable of detecting only a restricted range
of oncogenic events. Transfection of the retinoblastoma gene (13r^)
into an immortalised cell, for example, would not produce a tumori¬
genic cell, as the normal homologue (13q+) would still be present.
However, transfection of the normal homologue (13q+) into a
tumorigenic cell line containing only the retinoblastoma gene
(13qrk), would be expected to convert that tumorigenic cell line into
a non-malignant line. It is therefore clear that transfection
studies can be a very powerful tool in elucidating the molecular
mechanisms underlying malignant development. If other studies have
already yielded information as to the structure and/or location of
the gene involved.
The third fruitful experimental approach is high resolution
chromosome banding of malignant cells. Although many of the steps
involved in malignant change are submicroscopic, several consistent
visible rearrangements have been reported (Rowley 1982; Mitelman
1984). The easiest neoplastic cells to examine in this fashion come
from haematological malignancies, and the first translocations
identified were the 9:22 translocation in chronic myelogenous
leukaemia and the 8:14 translocation in Burkitt's lymphoma (Klein
1983; Heisterkamp 1983; Groffen 1984). Both these translocations
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involve previously identified oncogenes, c-abl and c-myc
respectively, but three new oncogenes, bcl-1, bcl-2 and tcl-1 have
been identified by similar studies in B-cell leukaemia, B-cell
lymphoma and T-cell leukaemia (Tsujimoto 1984, 1985; Croce 1985).
Combining these three experimental approaches, around 45
sequences in the human genome have so far been classed as proto-
oncogenes (Bishop 1983; Bloomfield 1988), although this number may
well increase.
Methods of activation
Proto-oncgenes are activated to become tumorigenic by a variety
of changes in either their structure or their regulatory elements.
1 Point mutation.
The three members of the ras gene family, Harvey ras, Kirsten
ras and N-ras, were identified by transfection experiments from a
bladder carcinoma cell line, a lung carcinoma cell line and a neuro¬
blastoma cell line (Der 1982; Shimizu 1983a, Fasano 1983; Shimizu
1983b). c-Harvey ras shares extensive homology with the oncgene of
the Harvey murine sarcoma virus (McBride 1982; Schwartz 1983) and c-
Kirsten ras is homologous to the Kirsten sarcoma virus (Chang 1982).
These three genes are very similar (Ellis 1981), although dispersed
through the human genome, Harvey ras on lip (McBride 1982; de
Martinville 1983), Kirsten ras on 12p (Jhanwar 1983), and N-ras on lp
(Hall 1983), encode three very similar proteins of 21,000 molecular
weight, known as p21 (Capon 1983; Taparowsky 1983; Lacal 1984).
Sequencing the proto-oncgene and the activated oncgene has
revealed that, in each case, a single point mutation activates the
proto-oncogene producing an abnormal p21. In Harvey ras this
mutation is in codon 12 or codon 61 (Reddy 1982; Goldfarb 1982).
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Injection of the abnormal Harvey ras p21 into immortalised cells
transforms them into tumorigenic cells, indicating that the single
amino acid substitution in the protein product is enough to confer
the malignant phenotype (Taparowsky 1982).
2 Increased transcription
Abnormally high levels of the normal p21, induced by increasing
the rate of transcription or the number of copies of the Harvey ras
proto-oncogene and thus the rate of translation of the normal protein
product, will also transform 3T3 cells in culture, thus a point
mutation is not essential (Parada 1982; Pulciani 1985).
Another proto-oncogene, c-erb B2, homologous to the avian
erythroblastosis virus located on 17q (Bister 1979; Jansson 1983) is
amplified in a variety of tumours and tumour cell lines (Ullrich
1984; Semba 1985; Fukushige 1986).
3 Production of a hybrid m-RNA
In chronic myeloid leukaemia, translocation between portions of
chromosomes 9 and 22 results in the juxtaposition of the oncgene c—
abl and the bcr (breakpoint cluster region), resulting in the trans¬
cription of a hybrid m-RNA molecule containing some coding exons from
bcr and all the coding exons except the first, from c-abl, which is
translated into an abl protein with a novel amino terminus derived
from the bcr gene (Gale 1984; Heisterkamp 1985). The abl product
has protein kinase activity and the fusion protein has altered enzyme
kinetics.
4 Dysregulation
Translocation of the oncgene, c-myc from chromosome 8 to chromo¬
some 14 seen in Burkitt's lymphoma results in dysregulation of c-myc
leading to a continued expression of the normal gene (Klein 1981;
16
Dalla-Favera 1982; Leder 1983; Taub 1984) whereas expression is
usually terminated as the cell differentiates (Curran 1984; Gonda
1984).
It is clear from the preceding sections that a large number of
oncogenes have been identified, and progress is being made in under¬
standing the various mechanisms by which a proto-oncogene becomes
activated, to cause a wide variety of human tumours. Those oncgenes
that have been implicated in human breast cancer, and their possible
contribution to the aetiology of the disease will be examined in the
next section.
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4 ONCOGENES IMPLICATED IN HUMAN BREAST CANCER
c-myc
Amplification of the proto-oncgene c-myc, on chromosome 8, has
been reported in a variety of carcinoma cell lines (Little 1983).
Between 20 and 30% of primary breast tumours show amplification of
this gene (Escot 1986; Varley 1987), but elevated levels of
expression have been reported in up to 80% of breast tumours (Kozbar
1984; Lee 1984). Thus amplification is not essential for high
levels of expression, although in most cases, amplification leads to
high levels of c-myc m-RNA.
Amplification of c-myc was significantly more frequent in
patients older than 50 years of age at presentation in one study
(Escot 1986), but was not linked to oestrogen or progesterone
receptor status, tumour grade or axillary node metastasis at
presentation. Another study (Varley 1987) found no correlation
between amplified c-myc and oestrogen receptor status, menopausal
status, or stage of the disease; but there was a significant
correlation between c-myc amplification and a poor prognosis as
measured by early recurrence of disease or death.
Although these studies examined fairly small numbers of
patients, they suggest that amplification of c-myc may well be a late
event in progression of a breast tumour. This suggestion ties in
with the finding that another member of the myc family N-myc is
amplified in Grade 2 and 3 neuroblastomas, but not in Grade 1 neuro¬
blastomas (Brodeur 1984).
There have been two independent reports of a rearrangement of
the c-myc locus in breast tumour DNA (Escot 1986; Varley 1987).
This rearrangement has been extensively mapped (Varley 1987) but the
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very low frequency with which it occurs, twice in a total of 162
tumours studied in the two reports, suggests that this event is
unlikely to be of great significance in the development of breast
cancer.
erb B2
Transfection studies with DNA from chemically-induced rat neuro-
glioblastomas identified an oncgene, named neu. Two other groups
independently isolated a similar oncogene and named it HER-2 and c-
erb B2. Subsequent analysis has revealed that all three genes are
the same (Shih 1981; Coussens 1985; Semba 1985). This gene codes
for a protein similar to, but distinct from, epidermal growth factor
(Schechter 1984; Coussens 1985) and is amplified 5- to 10-fold in a
mammary carcinoma cell line (King 1985). It was then reported
(Slamon 1987) that 18% of primary breast tumours have amplification
of erb B2 from 2- to 10-fold, and the only significant clinical
pathological correlation established was with metastatic lymph node
invasion. A second study identified erb B2 amplification in 40% of
patients who were lymph node-positive at presentation, and in this
subgroup of patients there was a strong correlation between erb B2
amplification and disease-free interval and survival, with erb B2
amplification being a poor prognostic factor (Slamon 1987).
One group, which looked at both c-myc and erb B2 amplification
reported that both genes are not amplified in the same tumour, while
the prognosis for patients with amplification of one of them is
essentially the same, irrespective of which gene is amplified, and
significantly poorer than for patients in whom neither gene is
amplified. This suggests that c-myc and erb B2 interact in some way
in the normal cell to regulate cell proliferation and that disturb-
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ances of regulation of either sequence in malignant breast epithelium
may result in the same clinical phenotype, i.e. poor short-term
prognosis (Varley 1987).
int-2
Mouse mammary tumour virus has been identified as a biological
agent associated with a high incidence of breast cancer in certain
inbred strains of mice (Moore 1974; Varmus 1982). No transforming
oncogene has been identified in the virus and a high percentage of
mammary epithelial cells may be productively infected yet still
maintain a normal phenotype. Tumours are rare, relative to the
total numbers of infected cells, and usually appear after a delay of
several months following initial infection. This pattern of
tumorigenicity suggested the possibility of insertional mutagenesis
with perturbation of expression of endogenous host proto-oncgenes
(Varmus 1982; Nusse 1984). In most MMTV-induced mammary cancers,
proviral insertion has been detected in one or other of two distinct
loci designated int-1 and int-2 (Nusse 1984; Dickson 1984). Genes
homologous to mouse int-2 have been identified in other mammalian
species including man (Casey 1986) and the human int-2 gene has been
mapped to llql3 (Casey 1986).
Amplification of int-2 has been reported in 4 out of 46 primary
breast tumours, all of which had metastised to regional lymph nodes
at presentation and all four behaved aggressively, progressing within
3 to 8 months despite intensive chemotherapy (Zhou 1988).
All the studies quoted in this section, and most strikingly the
last study, suggest that amplification of oncogene sequences occurs
in only a proportion of tumours and tends to generate aggressive
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malignant behaviour. It is therefore likely to occur late in the
lifetime of a neoplasm and to be of more importance in the
progression of the disease rather than its aetiology.
Harvey ras
An activating point mutation in codon 12 of the Harvey ras gene
has been identified in 80% of rat mammary carcinomas induced by
nitroso-methyl urea (Sukumar 1983), and in a human cell line derived
from a rare mammary carcino-sarcoma (Kraus 1984) but has not been
identified in primary breast tumours (Theillet 1986). However,
several groups have reported high levels of the normal protein
product p21 (Ohuchi 1986; Horan-Hand 1984, 1986; Whittaker 1986)
and Harvey ras m-RNA (Spandidos 1984) in up to 70% of human primary
breast tumours. One report correlates high levels with p21 with
larger tumours, metastatic axillary lymph node involvement at
presentation, and a shorter disease-free interval (Clair 1987),
suggesting that tumours with a high level of p21 exhibit more
aggressive behaviour, and that measurement of p21 in breast tumours
might be a useful prognostic indicator.
£53
p53 is a very interesting gene, which has perhaps received less
attention than it deserves in relation to human malignant disease.
The product, a protein of molecular weight 53,000 is a DNA binding
nuclear protein found in a wide variety of transformed cell systems.
Several studies have indicated that the expression of the p53
gene is associated with cell cycling and cell proliferation (Reich
1984; Mercer 1985) suggesting that it normally functions in the
control of cell growth.
21
The gene was first identified by immunological techniques (Lane
1979; DeLeo 1979), but there was a lag of 5 years before
demonstration of its oncogenic potential as an immortalising gene
(Jenkins 1984). Transfection of a codon 12-mutated ras gene will
only transform an immortal cell into a tumorigenic cell, but
cotransfection with p53 will transform rat embryo fibroblasts into
fully malignant cells (Eliyahu 1984; Parada 1984).
However, in this early work it was essential to have p53
expression markedly enhanced by powerful viral promotors (Eliyahu
1984). Jenkins (1985) transfected p53 genes mutated in vitro and
linked to a relatively weak promotor into rat embryo fibroblasts, and
was then able to induce transformed foci by secondary transfection
with an activated ras gene. These mutated p53 genes coded for
mutant proteins which were much more stable in the cell, and it
therefore seemed that p53 could only act as an immortalising gene, if
the cellular protein levels were abnormally high, either through
increased transcription or reduced protein breakdown. However,
transfection of p53 from normal mouse liver has recently been
reported to immortalise rat embryo fibroblasts (Rovinski 1988).
Whether this gene has, in fact, mutated in vivo remains an open
question (Oncogene 1988).
Elevated levels of the p53 protein were initially reported in
24% of breast cancers, particularly high-grade tumours (Crawford
1984). A subsequent report confirms this, finding high levels of
the protein p53 in 15% of primary breast cancers, significantly
correlating with histological Grade III tumours, with low levels of
oestrogen receptor protein, and high levels of epidermal growth
factor receptor (EGFR) protein (Cattoretti 1988).
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Low levels of oestrogen receptor protein (Moore 1983; Williams
1987) and high levels of EGFR protein (Sainsbury 1985, 1987) are both
accepted as poor prognostic indicators in breast cancer.
This gene's ability to cooperate with mutated ras in transform-
ing mortal rat fibroblasts, its elevated expression in the percentage
of apparently aggressive human breast cancers, and its localisation
in the human genome to the short arm of chromosome 17 (Isobe 1986;
McBride 1986; Miller 1986) suggests that examining chromosome 17 in
breast cancer patients might well be fruitful.
Having discussed the major oncogenes so far implicated in breast
cancer, we will now turn to examine the various strategies worth
pursuing in the search for those genes determining susceptibility to
breast cancer.
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4 THE SEARCH FOR BREAST CANCER "SUSCEPTIBILITY" GENES
Identifying tumour suppressor genes
In the preceding section I have argued that almost all the
reported alterations in known oncogene sequences in human breast
cancer are correlated with various parameters of aggressive tumour
behaviour, and therefore likely to be late events in the tumour's
lifespan. However, the inference from the findings in retino¬
blastoma would justify a comparison of DNA from both hereditary and
non-hereditary "early" tumours with DNA from somatic tissue, in order
to try and identify sequences which have been lost in these "early"
tumours. This approach has been greatly facilitated by the recent
identification of a large number of highly polymorphic DNA sequences
(White 1985; Barinaga 1987). Because they are very polymorphic, a
high percentage of individuals are constitutionally heterozygous, and
it is therefore clearer if the tumour DNA has lost an allele.
This rather theoretical concept has recently gained strong
experimental support from studies on familial polyposis coli and
colorectal carcinoma.
Following a case report of an interstitial deletion on 5q in a
mentally retarded patient with features suggesting familial polyposis
coli, but without appropriate family history (Herrera 1986) a highly
polymorphic "minisatellite" probe, mapping to 5q34 (Wong 1987),
revealed loss of a portion of 5q in up to 40% of sporadic colorectal
carcinomas (Solomon 1987). At the same time formal linkage analysis
using several other polymorphic 5q probes localised the gene for
familial polyposis coli to 5q 21-22 (Bodmer 1987; Leppert 1987). I
shall return to the theoretical basis and applications of linkage
analysis in the third part of this section.
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Reduction of a heterozygous marker to homozygosity in tumour DNA
has been reported in a variety of other cancers. In Wilm's tumour
(nephroblastoma), hepatoblastoma and rhabdomyosarcoma a consistent
deletion on lip has been reported (Koufos 1985).
Two groups have reported loss of a Harvey ras allele (mapping to
the tip of lip) in a significant proportion of breast cancers
(Theillet 1986; Yokota 1986), and one of these groups has reported
that the most frequent loss of sequences occurs between the beta-
globin and parathyroid hormone loci on lip (Ali 1987).
Loss of heterozygosity in a number of chromosomal locations has
also been reported in lung cancer (3p) (Kok 1987), renal cell
carcinoma (3p) (Zbar 1987), transitional cell bladder carcinoma (lip)
(Fearon 1985), osteosarcoma (13q) (Dryja 1986), uveal melanoma (2)
(Mukai 1986), acoustic neuroma/meningeoma (22) (Seizinger 1986), and
adrenal adenoma (lip) (Hayward 1988a).
The situation has been further complicated by reports of loss of
heterozygosity on 17p in 80% of colorectal carcinomas (Fearon 1987),
and on 13q in 60% of breast carcinomas (Lundberg 1987).
It is quite possible that these reports are compatible with each
other (Lancet 1988), as it is widely accepted that carcinogenesis is
a multi-step process and loss of two or more tumour suppressor
sequences might be essential before a cell can express the fully-
blown malignant phenotype.
Unusual allele distribution
The second potentially useful strategy is to examine different
populations for an unusual distribution of alleles of a particular
marker. The well-known finding that both gastric carcinoma and
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pernicious anaemia occur more often in individuals of blood group A
is a good example, but due to the large number of unaffected individ¬
uals of blood group A, it is of no help in screening for gastric
carcinoma.
On the other hand 90% of patients with ankylosing spondylitis
have the histocompatibility antigen HLA B27, and I shall return to
the importance of this in screening when I examine linkage analysis
(Tiwari 1985).
It is possible to identify several polymorphic forms of the DNA
sequence bearing the Harvey ras proto-oncogene in the normal
population, by DNA digestion and Southern blotting (see Section 5).
Using this technique in 1985, Krontiris reported his findings in a
group of patients with a variety of haemopoietic and solid
malignancies including a small number of breast cancers. In the
normal population, he identified four common c-Harvey ras alleles and
a number of rare alleles, and in cancer patients he found a
significantly higher frequency of rare alleles. He suggested that
possessing a rare Harvey ras allele indicated that the individual
would be more susceptible to development of cancer. Several groups
have now repeated this work and in general it has not been
substantiated.
Heighway (1986) reported a preponderance of one of the common
alleles in patients with non-small cell lung carcinoma but no
increase in frequency of rare alleles in either small cell lung
cancer or non-small cell lung cancer. Similar studies have reported
negative results in myelodysplasia (Thein 1986), colonic adeno¬
carcinoma (Ceccherini-Nelli 1987), sporadic and familial melanoma
(Gerhard 1987), and Wilm's tumour (Hayward 1988b), although an
increased frequency of rare Harvey ras alleles has been reported in
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bladder carcinoma (Hayward 1988b), and a large series of patients
with breast cancer (Lidereau 1986), in which 104 breast cancer
patients and 56 controls were examined. 58.6% of the 208 alleles in
breast cancer patients were "common" compared to 91% of the 112
control alleles. Lidereau and colleagues reported no correlation
between presence of a rare allele and any clinico-pathological
factors. In all the studies quoted, the frequency of each of the
four common alleles in the control populations are very similar,
although Lidereau's estimation of the molecular weight of these
common alleles differs by up to 800 base pairs from that of
Krontiris. These differences are ascribed to experimental error.
The differences in molecular weight between the rare and common
alleles identified is never more than 300 base pairs and there appear
to be no similarities between the rare alleles identified in the
separate studies of Kronitiris and Lidereau.
Whether there is an increased frequency of rare Harvey ras
alleles in any form of cancer remains an open question, which will
only be answered by more meticulous studies with larger numbers of
patients.
Lidereau's group has also reported an unusual allele of the c-
mos proto-oncgene on 8q 22 in 6 out of 75 breast cancer patients
(Lidereau 1985) but the significance of this is obscure in the
absence of a formal linkage analysis.
Linkage analysis
The most practical approach to locating the gene for suscepti¬
bility to breast cancer is by the technique of linkage analysis,
based on the segregation of defined genetic markers in affected and
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unaffected family members (Yates 1986). The human genome is
composed of genes arranged in a linear fashion along the 23 pairs of
chromosomes. Genes which are close together on the same chromosome
tend to be transmitted together - i.e. to segregate non-
independently. Genes on different chromosomes segregate
independently so that every possible combination of alleles appears
with equal frequency in the gametes as illustrated by Figure 1. The
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Fig. 1. Independent assortment of alleles at meiosis for a disease locus
(alleles D and d) and a marker locus (alleles T and t) on different
chromosomes
If the disease gene and the marker gene are physically very
close together, they will be transmitted together, so that the






Fig. 2. Absence of independent assortment of alleles at meiosis for
disease and marker loci very close together on the same chromosome
(tight linkage).
This depature from independent segregation is termed "linkage",
with D and T being very tightly linked in the examples shown. If D
and T are slightly further apart on the chromosome, the two genes may
well be transmitted together but because they can segregate by
crossing over and recombination at meiosis, a few gametes with
genotypes Dt or dT will appear, as illustrated in Figure 3.
Figure 3
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Fig. 3. Disease and marker loci nearby on the same chromosome
showing linkage. The recombination fraction is 20%.
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These gametes are known as recombinants and the proportion of
recombinant gametes in the total pool is the recombination fraction.
The further apart the two genes are, the more likely it is that
recombination will occur, until eventually the two genes will appear
to be segregating independently as all four possible genotypes will
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Fig. 4. Disease and marker loci far apart on the same chromosome
mimic independent assortment and linkage cannot be detected. The
recombination fraction is 50%.
The markers used in linkage analysis must be polymorphic, (i.e.
more than one allelic form found in the population), and ideally the
chromosomal location should be known. After identifying which
allelic forms of the marker are present in every individual (both
affected and unaffected) in a family, it is possible to calculate, A:
the probability of the observed distribution occurring by chance if
there is no linkage between the marker gene and the disease and, B:
the probabilities of such a pattern appearing if there is linkage at
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different recombination fractions. The logarithm of B/A known as
the "lod" (logarithm of odds) score, is calculated for various re¬
combination fractions. To obtain statistical significance it is
usually necessary to combine data from several families and the lod
scores from each family for each recombination fraction can be added
together. A lod score greater than +3 is usually taken as demon¬
strating significant linkage but obviously the more families
examined, the greater the confidence one can place in the lod score.
King, Go and colleagues (King 1983; Go 1983 ) used segregation
analysis to identify 10 families showing genetic transmission of a
breast cancer trait and performed linkage analysis using 21
independent polymorphic markers. They suggested that in 7 families
there was significant linkage between an autosomal dominant gene for
susceptibility to breast cancer and the enzyme glutamate-pyruvate
transaminase (GPT), the gene for which is located on chromosome 16
(Wijnen 1982; McKusick 1982). Go (1983) reported a lod score of
+1.95, at a recombination fraction of zero and accepted that such a
result should be viewed with caution. When a larger number of
families was examined it was conclusively shown that there was no
linkage between GPT and susceptibility to breast cancer (McLellan
1984).
Confusion sometimes arises between the terms "linkage" and
"association" in the context of genetics. As explained, linkage
between two DNA sequences means that they are physically close
together in the genome hence if one is polymorphic, so that
inheritance of the different alleles can be traced within a family,
it can be used to "tag" the other sequence. It does not follow that
the same allelic forms of the two sequences are linked in all cases.
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For example, in the case illustrated in Figure 2, a single chromosome
carries D and T in tight linkage, so that "T" would serve as a marker
for "D" in this family. In another family however, the relevant
chromosome might carry the alleles D and t, in which case the marker
for "D" would be "t". In other words, there is no functional
relationship between the gene with alleles Dd and that with alleles
Tt. The important practical consequence is that even if strong
linkage is established between these genes, there is no purpose in
screening a population, say for carriers of the "t" allele, since one
could not predict which of the individuals so identified would also
carry "D". That type of prediction is valid only within each
family.
"Association" is quite a different matter. The term implies
that a particular allele of a given gene is over-repeated among the
total population of patients with a particular genetic disorder.
There are, for example, over 100 diseases associated with individual
alleles of the major histocompatability system (Tiwari 1985). The
associations between HLA-B 27 and ankylosing spondylitis or DR 4 and
rheumatoid arthritis are well-known instances. These associations
hold across family boundaries (although, interestingly, they may not
apply in all racial groups) and can therefore be useful in population
screening. Association in this sense may come about because the
disease arose through a single mutational event affecting a gene so
close to the "marker" sequence, that the disease and marker alleles
have never become separated through the succeeding generations.
This so-called "founder effect" implies that all the affected
individuals in a population are actually related so they may not be
aware of it. An equally likely mechanism however, is a causal
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relationship between the marker allele and the disease itself. In
other words, individuals with the HLA-type B 27 are at risk from
ankylosing spondylitis, not because an "ank-spond" gene lies close to
the HLA complex on the short arm of chromosome 6, but because the B
27 gene product is actually involved in the aetiology of the disease.
Returning to the problem of genetic susceptibility to breast
cancer, the search for linkage in the strict sense, simply means
extension of the approach used by King, Go and their colleagues,
namely the analysis of large numbers of randomly chosen, polymorphic
markers (Nakamura 1987) in families with multiple cases of disease
occurring before the menopause. An alternative approach would be to
try to identify "candidate" genes suspected, for one reason or
another, of possible involvement in breast cancer. DNA sequences
which have been lost in tumour tissue, and represent putative tumour
suppressor genes, are obvious candidates for this approach. Until
recently, the shortage of useful genetic polymorphisms has restricted
both of these approaches, but the situation has been transformed by
the discovery of DNA restriction fragment-length polymorphisms as
discussed in the next section.
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5 SOUTHERN BLOTTING AND RESTRICTION FRAGMENT-LENGTH POLYMORPHISMS
Native DNA is a double-stranded helix, and because adenine must
be opposite thymidine, and guanine opposite cytosine, a single strand
of DNA uniquely defines its complementary strand of DNA or RNA.
Under appropriate conditions of pH, temperature and ionic
strength, single-stranded DNA or RNA fragments will hybridise with
complementary single strands of DNA. The stability of the double-
stranded complex ("hybrid") depends upon the degree of comple¬
mentarity between the two nucleic acid strands. By increasing the
pH or temperature or altering the ionic strength, hybridisation
conditions can be made more stringent until only strands that are
perfectly matched at every base pair will remain as hybrids. This
property is exploited in the technique of gene probing.
After extraction from the lysed cells and purification, as
described in Materials and Methods section, DNA is digested with a
restriction enzyme. Many different restriction enzymes, isolated
from bacteria and fungi, are now commercially available. Each
enzyme recognizes a specific base sequence in double-stranded DNA and
cuts both strands wherever that sequence occurs (Roberts 1983). The
fragments thus produced can be separated by electrophoresis in an
agarose gel. The shorter fragments will move faster through the gel
and so travel further away from the origin in a given time than
large, heavier fragments (Steel 1984).
It is much easier to work with DNA on a solid support than in a
gel and therefore the DNA is transferred onto either nitrocellulose
paper or a nylon membrane by a method first described by Dr E M
Southern (1975). This maintains the spatial relationship between
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the DNA fragments generated by the gel electrophoresis. After
"denaturing" the DNA with NaOH, to separate the two strands, the gel
is placed on a glass plate which has been overlaid with a sheet of
filter paper, with both ends dipping into a concentrated salt
solution. The membrane is placed on top of the gel and pressed down
onto it with a heavy weight. The salt moves down its concentration
gradient carrying the DNA from the gel to the membrane, and the
weight assists by gradually compressing the gel, forcing the DNA out.
After this overnight "blotting" procedure, the membrane is exposed to
ultraviolet light for 2 to 5 minutes. This links the single strand
DNA to the membrane by covalent bonds.
The next step is to create a labelled DNA or RNA probe (i.e.
millions of identical copies of a particular base sequence). The
probes themselves are obtained by cloning the required piece of DNA
as an insert in a virus-like vector which will grow in a bacterial
host, usually E.coli.
The most common method of labelling a DNA probe is "nick trans¬
lation"; a segment of double-stranded DNA is incubated with a
mixture of 3 unlabelled nucleotides plus 1 nucleotide containing
OO
radioactive p atoms. The enzymes DNAase and DNA polymerase I are
added. The DNAase introduces breaks ("nicks"), at random in one DNA
strand and the DNA polymerase moves along that strand cutting out
nucleotides and then replacing them, using the other strand as a
template. In the course of this repair phase p-^ labelled nucleo¬
tides are introduced into the DNA.
Another method used to label DNA probes to a higher specific
activity with p^2 is "random priming". The probe is first denatured
by boiling, then a mixture of 3 unlabelled nucleotides, a p^2
labelled nucleotide, bovine serum albumen, a primer, and the "Klenow"
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fragment of DNA polymerase are added and left at room temperature for
3 to 5 hours. The "Klenow" fragment, using the single stranded
probe as a template, moves along the probe, adding nucleotides onto
the primer in the correct order and thus generates labelled probe
sequences. This method is advantageous when only very small amounts
of the probe are available.
The membrane bearing the imprint of the original DNA gel
fragments, is immersed in a complex hybridisation solution,
containing the labelled probe, shaken overnight at 68°C and then
washed to remove unhybridised probe. If stringent washing
conditions are used, the probe will hybridise only to these fragments
of DNA on the filter, to which it is exactly complementary. After
autoradiographic exposure (1 to 10 days at -70°C), one or more
discrete bands appear on the film. These bands correspond to the
DNA fragments on the membrane to which the probe has hybridised and
the sizes of these fragments can be determined from the position of
the bands.
At least 90% of the DNA in a human cell does not encode any
protein product - i.e. does not consist of "genes". While this
material is not necessarily devoid of function, it is evidently much
more tolerant of variation in base sequences than the genes them¬
selves. Hence, within the species there is much more polymorphism
of the non-translated DNA than of the genes. One aspect of this
polymorphism is the gain or loss of restriction enzyme cleavage
sites, the positions of which can vary considerably from one indi¬
vidual to another. Thus when DNA is cleaved with a restriction
enzyme and the Southern blot probed with a particular labelled
sequence, the size of fragment bearing the complementary sequence is
36
quite likely to show some variation within the population. This
"restriction fragment-length polymorphism" (RFLP) provides an
enormous pool of genetic markers, since the positions of restriction
sites are still sufficiently stable for the DNA fragment lengths to
behave as alleles obeying simple laws of Mendelian inheritance.
"Anonymous" DNA probes, recognising sequences that are not
necessarily parts of structural genes, now represent a major resource
in human gene mapping and genetic analysis. They may be used simply
to increase the pool of "random" polymorphisms for the conventional
"shotgun" approach to linkage studies or they may serve to provide
polymorphic markers for adjacent candidate genes. The latter
application ironically, tends to blur the distinction just made
between "linkage" and "association" since the candidate gene, by
definition, will be causally related to the disorder (implying
association). Nevertheless, when the allelic forms of that gene are
identified on the basis of restriction fragment-length polymorphism
rather than by the putative mutation directly responsible for the
disease, then any observed correlation between a particular allele
and disease susceptibility will apply only within an individual
family - i.e. we are dealing with true "linkage". Of course, in
such an event, the logical course would then be to analyse the
implicated gene in sufficient detail to permit direct identification
of the crucial DNA lesion which would, in turn, provide a basis for
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The chromosomal localisation and restriction enzymes used in
this study are tabulated in the experimental data section. All
these probes were grown in the MRC unit.
Harvey-ras; pEj
The 6.4kb Bam HI fragment of human genomic DNA containing the
transforming "oncgene" from a bladder carcinoma cell line.
Vector-pBR 322
Tets, ampr
Wash 0.1 SSC (Shih 1982)
Beta-globin;Pst B
A 4.4kb Pst I fragment of human genomic DNA.
Vector-pBR 322
Tetr, amps
Wash 0.5 SSC (Orkin 1982).
PTH;pEB 3
A 2.1kb Eco RI fragment of human genomic DNA.
Vector pBR 322
Tetr, ampr
Wash 0.1 SSC (Mayer 1983).
Calcitonin;phT-3




Wash 0.5 SSC (Craig 1982).
Catalase;cat 4-1
An llOObp Pst I fragment from a cDNA liver library.
Vector pKT 218
Tetr, amps
Wash 0.5 SSC (Boyd 1986).
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FSH-B;pRS 1.2
A l.lkb Eco RI-SAC I fragment insert.
Vector pBR 322
Tetr, ampr
Wash 0.1 SSC (Watkins 1985; Glaser 1986)
ApllF9 Dll S49
A 15kb Bam HI insert from E67.1 DNA.
Vector EMBL 3
Repeat sequences must be removed by stripping with sonocated
placental human DNA.
Wash 0.1 SSC (Porteous 1987).
Apo A1;pAl
A 630bp Pst 1 fragment of cDNA from human liver.
Vector pBR 322
Tetr, amps
Wash 0.1 SSC (Glaser 1988).
Int 2;pSS6
A 900bp Sac I fragment of cDNA from human placenta.
Vector pSP 64
Ampr, tets.
Wash 0.1 SSC (Casey 1956).
Pepsinogen;pH PEP




Wash 0.1 SSC (Taggart 1985, 1987).
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Erb A2; pHeA2




Wash 0.1 SSC (Jansson 1983, Gosden 1986).
MHC Class II;pll-B-4
A l,080bp Eco Rl/Pst I fragment from a human cDNA library.
Vector pBR 322
Tetr, amps
Wash 0.1 SSC (Gustafsson 1984).
AMS 8;D5 S43.
A 7.0kb Bam HI fragment in L 47.1.
Vector L 47.1
Wash 0.1 SSC (Wong 1987)
YNZ 22




Wash 0.1 SSC (Nakamura 1987).
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Buffers and Solutions
Lysis buffer - 0.1M Tris HC1, 20mM NaCl, ImM EDTA, 0.2% SDS.
Chloroform: isoamyl alcohol 24:1.
7.5M amonnium acetate (578.lg in 1 litre).
Resuspension buffer - lOmM Tris HC1, 150mM NaCl, lOmM EDTA.
10T-0.5E - lOmM Tris HC1, pH 7.5, 0.5mM EDTA
20xSSC - 876.6g NaCl, 441.2g Na3 citrate in 5 litres.
0.1M Mg Cl2
Cryogenic storage solution - 50:50 L-broth/glycerol.
Tris/EDTA/glucose - 500ml, 50mM glucose, lOmM EDTA, 25mM Tris HC1 pH
8.0.
High salt solution - 3M K Ac, 2M acetic acid.
Dissolve K Ac in about 250ml of water, pH - 4.8 with acetic acid and
then make volume up to 500ml.
20xTAE gel buffer - 484g Tris base, 114.2ml acetic acid, 200ml 0.5M
EDTA in 5 litres.
Running buffer - 30% sucrose, 0.4% BPB.
Denaturing solution - 5g NaOH (0.5M), 219.15g NaCl (1.5M) in 2.5
litres.
Neutralising solution - 292.9g NaCl (2M), 394g Tris base (1M) in 2.5
litres.
Add HC1 to pH 5.5.
L-broth. - lOg tryptone, 5g yeast extract, 5g NaCl, 1ml IN NaOH in 1
litre.
T-broth. - 6g tryptone, 12g yeast extract, 2ml glycerol in 500ml.
Before innoculation add 50mls PO4 buffer.
PO4 buffer - 23gm KP^PO^, 125gm K2Hp0^ in 3 ]_itre.
NaOH/SDS - 0.2M NaOH, 1% SDS.
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Wash buffer - 0.1SSC - 50ml 10% NaPPi, 25ml 20% SDS, 25ml 20xSSC in 5
litres.
0.5SSC - 50ml 10% NaPPi, 25ml 20% SDS, 125ml 20xSSC in 5 litres.
Ficoll solution - 12.5% Ficoll, SG 1.077.
50xDenhart's solution, - 5g Ficoll, 5g polyvinyl pyrrolidene, 5mg BSA
in 500ml.
Alternative prehybridisation solution - 300ml 20xSSC, 50ml 50x
Denharts, 12.5ml 2% SDS in 1 litre.
Dextran prehybridisation solution - 150ml 20xSSC, 50ml 50xDenharts,
12.5ml 20% SDS, 50g Dextran sulphate in 500ml.
Dulbecco's modified eagle medium (Dulbecco 1959; Smith 1960)
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METHODS
Separation of lymphocytes (Boyum 1968)
1 One ml of whole blood was sent for high resolution chromosome
banding as previously reported (Yunis 1976).
2 Centrifuge remaining blood at 2.5K for 5 minutes.
3 Pipette plasma off and discard.
4 Make volume up to 20mls with DMEM and shake.
5 Layer 10ml of this sample onto 10ml Ficoll solution in a sterile
universal.
6 Add 10ml of lysis buffer to the other 10ml of blood in a 50ml
graduated plastic tube (Falcon).
7 Centrifuge Ficoll solution at 2.5K for 15 minutes.
8 Pipette off visible lymphocyte band and then wash with DMEM.
9 Wash the remainder of red cells and granulocytes in the Ficoll
sample, with DMEM then add to 10ml of lysis buffer.
10 Leave blood overnight in lysis buffer at 4°C.
11 Lymphocytes EB virus-transformed by Dr C M Steel as previously
described (Diehl 1964).
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DNA extraction from whole blood, tumour tissue, placentae and lympho-
blastoid cell lines (Gross-Bellard 1972)
1 Add 10ml whole blood to 10ml lysis buffer and leave overnight at
4°C.
2 Add 10ml water saturated phenol, shake vigorously and centrifuge
at 3K for 10 minutes.
3 Pipette off top layer, add 10ml of 24:1 chloroform isoamyl
alcohol, shake and centrifuge at 3K for 10 minutes.
4 Pipette top layer off, add 5ml 7.5M ammonium acetate, and 20ml
isopropyl alcohol, shake and leave overnight at-40°C.
5 Spool out any clumped, floating DNA with a glass rod.
6 Centrifuge at 3K for 15 minutes, then pour supernatant off and
resuspend precipitate in 10ml resuspension buffer. Add any spooled
out DNA on rod to this resuspension buffer.
6a If extracting from tumour or placentae the sample which was
stored at -70°C is finely minced with a single sided razor blade as
soon as it has defrosted enough to cut. Add 10ml resuspension
buffer. If extracting from lymphoblastoid cell lines, add sample to
10ml resuspension buffer directly.
7 Add lOOul 20% SDS to final concentration of 0.2%.
8 Add 50ul of lOmg/ml RNAse to final concentration of 50ugm/ml.
9 Incubate with occasional agitation at 37°C for half an hour.
10 Add lOOul of lOmg/ml proteinase K to final concentration of 100
ug/ml.
11 Incubate with occasional agitation at 37°C for 1 hour.
12 Add 10ml of ice cold water saturated phenol and shake.
13 Leave on ice for 20 minutes.
14 Centrifuge at 3K for 10 minutes.
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15 Pipette off top layer, add 10ml 24:1 chloroform isoamyl alcohol,
shake.
16 Centrifuge at 3K for 10 minutes.
17 Pipette off top layer, add 5ml 7.5M ammonium acetate, 20ml 100%
ethanol and shake.
18 Leave overnight at -40°C.
19 Spool out clumped DNA on glass rod then centrifuge at 3K for 15
minutes, pour off and keep supernatant at -40°C overnight.
20 Resuspend precipitate or spooled out DNA in 500ul of 10T.5E
buffer.
21 Recentrifuge supernatant at 3K for 15 minutes.
22 Pour off supernatant and resuspend any precipitate in same
10T.5E buffer used in stage 20 in order to keep DNA as concentrated
as possible.
23 Repeat 19, 20 and 21 till no further precipitate is seen.
Store DNA in 10T.5E at 4°C.
24 After 4-7 days in 10T-5E buffer, measure concentration of DNA in
sample.
25 Add lOul sample to 740ul distilled water, mix well and pipette
into glass spectrophotometer cell.
26 Measure absorbence at 260nm and 280nm in PYE SP 6/400 spectro¬
photometer.
27 If DNA is clean A260/A280 should be 1.8.
28 Calculate concentration. A reading of 1 at 260nm = a DNA
concentration of 50mg/ml. Therefore reading of absorbance x 50 x 75
= concentration in mg/ml.
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DNA digestion
1 Calculate the volume of lOug of genomic DNA.
2 To lOug of DNA add 4ul of the appropriate buffer (as listed in
the Materials section) in a stoppered Eppendorf tube (Treff).
3 Add sterile distilled water to final total volume of 38ul.
4 Add 2ul (20units) of restriction enzyme.
5 Mix thoroughly with Whirlimix (Jencons).
6 Spin briefly in an Eppendorf centrifuge (Sorvall microfuge).
7 Incubate overnight at 37°C.
- Note if digesting with Taq I, incubate at 65°C.
8 The following morning spin briefly in Eppendorf centrifuge to
remove condensed water from lid.
9 Add further 2ul of restriction enzyme.
10 Mix throughly with Whirlimix.
11 Spin briefly in an Eppendorf centrifuge.
12 Incubate for further 3-5 hours at 37°C to ensure complete
digestion (or 65°C if Taq I used).
13 Spin briefly in Eppendorf centrifuge.
14 Add lOul of running buffer.
15 Mix with Whirlimix.
16 Spin briefly with Eppendorf centrifuge.
17 Samples are now ready to load on agarose gel.
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Electrophoresis in agarose gel (McDonell 1977, Southern 1979)
1 All our samples are run in full size (20cmx25cm) 500ml gels.
2 Make gel by dissolving 4g purified agarose in 500ml lxTAE
buffer, weigh flask, stirrer, agarose and buffer.
3 Boil gel.
4 Reweigh and add distilled water to original weight.
5 Cool gel, while stirring, to 60°C.
- If using high frequency cutting restriction enzymes (Taq I,
MSP I) use 1% agarose gel; i.e. 5gm agarose in 500ml TAE buffer.
6 Prepare electrophoresis tank (BRL Model H4) by ensuring tray is
flat, stick autoclave tape to both ends of tray, and put correct comb
(i.e. with appropriate number of slots) in place.
7 When gel has cooled to 60°C, pour gel into tray removing any
trapped air bubbles with a pipette.
8 Leave gel until it has completely set.
9 Remove autoclave tape from end of tray.
10 Pour in a sufficient volume of lxTAE buffer to completely
submerge gel.
11 Remove comb carefully.
12 Slide a piece of coloured paper below wells to improve
visibility.
13 Load one sample into each well.
14 If a molecular weight marker is needed, load 0.4mg of Hind III
digested ADNA into the appropriate well.
15 Connect up pump (Crouzet lOrpm) to circulate buffer through a
beaker of ice. This is important to get lanes as straight as
possible by preventing buffer heating up or accumulation of ions in
various compartments of the tank.
51
16 Connect up tank, remembering DNA runs to anode.
17 Run at 60V for 16-48 hours.
- resolution of Bam HI fragments for probing with Harvey Ras
requires run of 48 hours. For the other probes used, gel ran for
16-20 hours.
18 Switch off current, mark one corner of gel for later orientation
of gel and membrane and immerse gel in 1 litre TAE buffer, with 50ul
of lOmg/ml ethidium bromide to final concentration of 0.5ug/ml for 30
minutes with occasional agitation (Sharp 1973).
19 Pour off buffer and destain with 1 litre distilled water for 10
minutes.
20 Place gel on UV transilluminator (UVP (Inc)) and wearing a
plastic visor look at gel, to detect incomplete digestion or squint
channels.
21 Photograph gel using bellows camera, orange filter and Kodak X
Pan 4147 film.
22 Denature DNA in gel by immersion in 1.25 litres of denaturing
solution with gentle agitation for 45 minutes.
23 Remove gel and neutralise by immersion in 1.25 litres of
neutralisation solution with gentle agitation for 1 hour.
- gel is now ready for blotting procedure.
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Southern blotting (Southern 1975)
1 Prepare blotting apparatus by placing a piece of glass (0.5cm x
23cm x 48cm) on a plastic tray (30 x 45cms) containing 1-2 litres of
20 x SSC buffer. On glass plate place a piece of 17mm filter paper,
with both ends immersed in 20 x SSC buffer.
2 Thoroughly wet filter paper with 20 x SSC buffer and remove all
trapped air bubbles by rolling glass pipette over paper.
- when not in use tank should be completely covered with cling
film to reduce evaporation.
3 Place a piece of 3mm filter paper on the 17mm paper, thoroughly
wet paper with 20 x SSC buffer and remove trapped air bubbles.
4 Remove gel from neutralising solution, shake off excess
solution, place on filter paper and remove trapped air bubbles.
5 Place cling film around gel, to completely cover tank, reducing
evaporation and preventing crystallisation of the very concentrated
salt solution.
6 Place a piece of Hybond N (Amersham) (20 x 23cm) over gel, and
remove trapped air bubbles.
7 Place two pieces of dry 3mm filter paper over Hybond N, then a
pile of white paper towels (Kleenex) then arrange green paper towels
(Scott Bowtowels) on this pile to give complete coverage of pile.
- this insures equal transfer of the DNA onto Hybond N.
8 Place plastic tray on towels, then two bricks and a 1kg weight.
9 Leave overnight.
10 Remove all towels and the two pieces of 3mm filter paper.
11 With ballpoint pen, mark heights of slots and cut corner on
Hybond, and name and date of filter.
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12 Peel Hybond membrane off gel and discard gel and single piece of
3mm filter paper, and recover whole blotting apparatus with cling
film.
13 Place Hybond membrane on a clean UV transilluminator (IVP
(Inc)), DNA side down and illuminate for 4 minutes.
- this covalently binds the DNA to the membrane.
The transilluminator must be calibrated for optimum length of
illumination as over exposure can break the covalent bonds already
formed, making it impossible to reprobe the membrane effectively.




Preparation and transformation of competent cells (Mandel 1970;
Dagert 1974)
Preparation
1 Inoculate a single colony of E.coli DH1 into lOOmls of sterile
L-broth, without antibiotics.
2 Shake for 5 hours at 37°C.
3 Measure optical density at 260nm in Pye SP6/400 spectrophoto¬
meter.
4 When OD reaches 0.5, centrifuge at 3K for 10 minutes at 4°C in
Sorval RC 5B).
5 Discard supernatant and resuspend cells in 25ml precooled 0.1M
CaCl2>
6 Centrifuge at 3K for 10 minutes at 4°c.
7 Discard supernatant and resuspend pellet in precooled 0.1M
CaCl2«
8 Centrifuge at 3K for 10 minutes at 4°C.
9 Discard supernatant and resuspend pellet in 5ml 0.1M CaC^.
10 To store, dispense into Eppendorf tubes (Treff) and freeze
immediately in a flask of liquid N2»




1 Add O.lug plasmid DNA to 100 1 of competent DH1 E.coli in an
Eppendorf tube and mix gently on ice.
2 Leave on ice for 30 minutes.
3 Place in 42°C water bath for 3 minutes to heat-shock cells.
4 Add lOOul L-broth without antibiotics and incubate at 37°C for 1
hour.
5 Plate lOOul onto an agar plate containing the appropriate
antibiotic, and spread with a glass spreader.
6 Incubate at 37°C upside down overnight.
Probe growing and extraction (Silhavy 1984)
1 Plate out a colony picked from a stab or from cryogenic storage
onto an agar plate with appropriate antibiotic at concentration of 50
ug/ml.
2 Incubate overnight at 37°C.
3 Pick one single colony and infect 25ml of T-broth containing
antibiotic at 50ug/ml in a 50ml blue tube (Falcon). Make 3 similar
tubes.
4 Incubate the 4 tubes overnight at 37°C in orbital shaker
(Gallenkamp) shaking at 210rpm.
5 Centrifuge at 3.5K for 15 minutes to precipitate bacteria.
6 Discard supernatant.
7 Resuspend pellets from 2 tubes in 2mls Tris/EDTA/glucose and
transfer into 50ml tube (Sarsted).
8 Add 4mls NaOH/SDS and mix well.
9 Leave for 10 minutes on ice.
10 Add 3ml high salt solution, and mix well.
11 Leave for 10 minutes on ice.
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12 Centrifuge at 10K for 20 minutes at 4°C in Sorval ultracen-
trifuge (RC5 B).
13 Pour precipitate through muslin into clean 50ml tube (Sarsted).
14 Add 0.6 volumes (5.4ml) of isopropyl alcohol and mix well.
15 Leave for 30 minutes at -40°C.
16 Centrifuge at 10K for 20 minutes in Sorval ultracentrifuge.
17 Discard supernatant.
18 Resuspend precipitate from both tubes in 3mls 10T.5E buffer and
transfer to 5ml plastic tubes (Sarsted).
19 Add 20ul of lOmg/ml RNAse to final concentration of lOOmg/ml.
20 Incubate at 37°C for 30 minutes.
21 Add 2ml water-saturated phenol and mix well.
22 Centrifuge at 3K for 10 minutes.
23 Pipette off top layer, add 2ml 50:50 phenol chloroform and mix
well.
24 Centrifuge at 3K for 10 minutes.
25 Pipette off layer. Add 2ml 24:1 chloroform isoamyl alcohol and
mix well.
26 Centrifuge at 3K for 10 minutes.
27 Pipette off top layer, add 1ml 7. 5M ammonium acetate and 4mls
absolute alcohol. Mix well.
28 Leave overnight at -40°C.
29 Centrifuge at 10K for 20 minutes.
30 Resuspend precipitate in 100 1 of 10T.5E. Store at -20°C.
31 Run 2ul of this solution on a minigel, (BRL H6), 0.8% agarose
with 0.5 gm/ml of ethidium to see how clean probe is.
- if the probe is clean enough, label as in Section 8.
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Cleaning up probe
There are two widely used methods
a) Gel electrophoresis
b) Caesium chloride gradients
We prefer to use gel electrophoresis,
a) Gel electrophoresis
1 Make 150ml 0.8% agarose gel without ethidium-bromide, in a midi
tank (BRL H5).
2 Pour gel, using 12 well comb, not a 2 well, preparative comb.
3 Pour in TAE buffer to cover gel and remove comb carefully.
4 Add 20ul of running buffer to lOOul of probe solution.
Whirlimix and spin briefly in Eppendorf centrifuge.
5 Load gel, filling each slot as fully as possible.
6 Load 0.4mg of Hind III ADNA in one slot, to act as molecular
weight marker.
7 Run gel at 60V for 3-5 hours, depending on molecular weight of
plasmid and insert being cleaned up. It is essential to run the
probe far enough so that a definite band can be seen, but running too
far results in broadening of the band, and the final concentration of
the probe will be very low.
8 Stain gel as in Section 4, steps 18-20.
9 Excise appropriate band with clean single-edged razor blade,
removing all excess gel.
10 Mince gel slice with razor and scoop gel into top of spinex tube
(Costar).
11 Centrifuge spinex tube in Eppendorf centrifuge for 30 minutes.
12 Recover liquid at bottom of spinex tube and check how clean and
how concentrated probe is by running another mini gel (BRL H6).
This method can also be used to isolate an insert, which has
been cut out of a plasmid.
58
Caesium chloride gradient (Yamamoto 1970)
1 After step 29, resuspend precipitate in 19.26ml 10T.5E buffer.
2 Weigh out 21.30g of Caesium chloride into a 30ml polyallomer
tube (Sorval).
3 Add 2.04ml of lOmg/ml ethidium bromide and mix well.
4 Pipette the resuspended probe in a layer onto the top of the
tube, and fill tube with a layer of liquid paraffin.
5 Tubes have to be accurately balanced to O.lgm.
6 Centrifuge at 40K for 18 hours at 20°C in Sorval OTD 65
ultracentrifuge.
7 Using the ultraviolet transilluminator (IVP Inc) a bright band
halfway down the tube can be seen.
8 Pipette off band in to a 10ml plastic tube (Sarsted).
9 Add equal volume (5-10ml) water-saturated butan-l-ol and mix
well.
10 Leave to stand in ice for 5 minutes.
11 Pipette off top layer and discard it.
12 Repeat steps 9-11 until the top layer is completely clear.
- this procedure removes the ethidium-bromide from the probe.
13 Add 2.5 volumes (25ml) of 75% ethanol.
14 Leave at -70°C for 30 minutes.
15 Thaw solution, then centrifuge at 8K for 20 minutes in Sorval
ultracentrifuge (RS 5B).
16 Discard supernatant.
17 Resuspend precipitate in lOOul 10T.5E.
18 Run 2ul on mini gel (BRL H6) as in step 12 above.
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Probe Labelling (Rigby 1977)
a) "Nick" translation
The majority of probes which have been used in this work were
labelled by nick translation using the Amersham kit (No 8160SB).
1 Add O.lug of probe DNA, 5ul of unlabelled nucleotide solution
(Solution A4), 2ul of P32 TTP (20 Ci) 5ul of DNAse/DNA polymerase
(Solution C) and sterile distilled water to give a final volume of
50ul
2 Mix gently.
3 Incubate at 16°C in water bath in cold room for 3-5 hours.
4 To estimate % incorporation; pipette lul of solution onto a
Whatmann B microfibre filter paper, place in a scintillation vial
(Motil platics), count for 0.1 minutes in Tricarb scintillation
counter (Packard model 3330) (Struhl 1987).
5 Remove filter paper, place on Buchner flask with vacuum pump,
and wash with 30ml of 5% TCA.
6 Place filter in scintillation vial containing 10ml 5% TCA and
count for 0.1 minute.
% incorporation = count in 4 and should be 30-50%-
count in 6
Specific activity = count in 6 x 10 (as counted for 0.1 minute)
x 4 (window on counter) x 10 (as O.lug as probe DNA was used) x
50 (reaction volume) and should be around 5 x 103 cpm/ug.
If dextran prehybridisation solution is used the labelled probe
must be separated from unincorporated nucleotides by ethanol
precipitation.
7 Add 20ul of lOmg/ml sonicated salmon sperm DNA solution to act
as a carrier for the probe.
8 Add 1/50 volume (l-2ul) of 3M NaOAc.
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9 Add 2 volumes (140ul) of 100% ethanol.
10 Mix briefly and leave at -40°C for 30 minutes.
11 Spin in Eppendorf centrifuge for 30 minutes.
12 Pipette off supernatant and discard, taking care not to disturb
precipitate.
13 Resuspend precipitate in 500ul of lOmg/ml sonicated salmon sperm
DNA.
14 Place in boiling water bath for 10 minutes to denature probe.
- probe is then ready to be added to membrane.
If the alternative prehybridisation solution is used, there is
no need to remove unincorporated nucleotides.
15 Add 500ul of lOmg/ml sonicated salmon sperm DNA, boil for 10
minutes and the probe is then ready to be added to the membrane.
Random priming (Jacobsen 1974; Feinberg 1983)
If the insert has been cut out of the plasmid, or very small
amounts of probe are available, random priming is the labelling
method of choice. We have routinely used the Amersham random
priming kit (RPN 1600Y).
1 If circular plasmid is used, it must be linearised by digestion
with an appropriate restriction enzyme, i.e. one will not cut out the
insert, but will cut at one site in the plasmid.
2 Add 25-200ng of probe, 5ul of unlabelled nucleotide solution,
5ul BSA/primer solution, 5ul of buffer, 2ul of P^ TTP (20 Ci).
5ul of "Klenow" fragment of DNA polymerase, and sterile distilled
water to give final reaction volume of 50ul.
3 Leave for 3-5 hours at room temperature, then test percentage
incorporation as before in steps 4 onwards.
- remove unincorporated nucleotides by ethanol precipitation as
above.
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Hybridisation (Southern 1975, Thomas 1980)
1 Make bag for membrane by heat-sealing a length of double-sided
plastic (Transatlantic Plastics).
2 Cut off corner of membrane previously marked with ballpoint pen
as the pen marks will be removed during this process. Place membrane
in bag and seal 3 sides with 2 seals per side.
3 Add 40ml of prehybridisation solution, preheated to 65°C in
water bath.
- we have used two prehybridisation solutions, as listed in the
materials section.
Dextran prehybridisation solution should not be used with the
Harvey-ras probe.
4 Remove as many air bubbles as possible, and heat-seal the top of
the bag twice.
5 Immerse membrane in shaking water bath at 65°C for at least 30
minutes.
6 Remove plastic bag from water bath and cut a small incision
through one layer of the plastic at the top corner and insert a
sterile blue Eppendorf tip (Gilson) into the hole- to ensure that
both layers of plastic have not been cut.
7 Remove blue tip and pipette in all the probe solution.
8 Remove air bubbles and reseal bag.
9 Wash outside of bag with water.
10 Ensure that probe has gone into the bag by placing the bag in
front of a Geiger counter (Mini Instruments Ltd).
11 Return bag to 65°C water bath and leave overnight.
12 Pour 500ml of wash buffer at 65°C into plastic tray.
- we have used 0.1 SSC wash buffer for the majority of probes,
and 0.5 SSC buffer for a few.
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13 Remove plastic bag from water bath and cut off three sides under
level of wash buffer.
14 Slide out membrane and discard plastic bag.
15 Pour away wash buffer and add a further 500ml of wash buffer.
16 Agitate tray in shaking oven (Gallenkamp) at 65°C for 10
minutes.
17 Pour away wash buffer and add a further 500ml and replace in
shaking oven for 10 minutes.
18 Repeat step 17 again.
19 Remove membrane from wash buffer and place between two sheets of
clean, dry 3mm Whatmann's filter paper for 30 seconds.
20 Place membrane on a clean sheet of 3mm filter paper, DNA side
up, cut to the size of the membrane, remembering to cut off the
corner of the paper to allow later orientation.
21 Wrap membrane and filter in cling film, making three cuts in the
right-hand side of the cling film and squeezing out any excess air.
22 Place wrapped membrane in X-ray cassette.
23 Preflash a piece of X-AR Kodak Omat film, with one thumb over
lower corner, to allow orientation of autoradiograph.
24 Place film exactly over membrane, (in total darkness), and close
X-ray cassette firmly.
25 Leave overnight at -70°C.
26 Remove film (in total darkness) and develop it in autoradio¬
graphic developer (RGII Fugi X-ray film processor).
27 The bands are likely to be very faint, but it will be clear if
the membrane has been properly washed.
28 Repeat steps 23 and 24.
29 Leave at -70°C for 10-14 days, then develop second film as in
step 26 to give final autoradiograph.
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Reprobing a Hybond-N membrane
1 Remove cling film from membrane.
2 Place membrane in 400ml of boiling 0.1% SDS.
3 Switch off hot plate and allow solution to cool.
4 Repeat steps 19-25 to ensure that the first probe has been
washed off completely.
- if the filter is clean it can be reprobed with a different
probe following the method already described.
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Clinical Material
Tumour samples were collected from 100 patients undergoing Patey
mastectomy or wide local excision, immediately frozen on dry ice, and
stored at -70°C until DNA extraction.
All patients had presented with palpable breast lumps and were
referred by their general practitioners to the breast clinic in the
Royal Infirmary of Edinburgh. Patients with T4 tumours or with
distant metastases at presentation were excluded, as they were
usually treated by chemotherapy in the first instance. All patients
underwent either axillary lymph node sampling or axillary clearance.
20ml of venous blood was collected from these patients (with their
informed consent) and transferred to a sterile Universal with 200U of
sodium heparin. Similar 20ml samples were collected from both
affected and unaffected members of the large kindred described in the
section on Experimental Data. Blood samples were immediately
separated and lymphoblastoid cell lines set up as in the Methods
section.
One portion of tumour was placed on ice and the oestrogen
receptor protein concentration immediately assayed by Dr R A Hawkins
(Lister Laboratories of the University Department of Clinical
Surgery), by a saturation analytical method with separation of free
and bound hormone using Dextran-coated charcoal adsorption as
previously described (Hawkins et al 1981).
Samples from patients who had received a synthetic anti-
oestrogen Tamoxifen were also examined by enzyme immunoassay (ER-EIA
Kit, Abbott laboratories, as in Leclerq 1984). Tamoxifen interferes
with the former but not the latter assay.
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The greatest diameter of these excised tumours was accurately
measured in millimetres by Drs T J Anderson and J J Going of the
Department of Pathology. They were classified into histological
types (Page 1988), examined for vascular invasion, lymphatic invasion
and in situ carcinoma.
Lymph nodes were also examined histologically for metastases.
Information on age at presentation, menopausal status, family
history, clinical tumour staging, and drug history was available on
all these patients.
Samples from 100 placentae were collected with the cooperation
of the Obstetrics and Gynaecology Department of the Western General
Hospital and stored at -70°C until DNA extraction as in the Methods
section.
Details of the pedigree of the large kindred described in the
Experimental Data section were ascertained, drawn and verified by Mrs
S Collyer and Mrs R De Mey in the Registry of the MRC CAPCU. The




1 Bam HI Harvey-ras alleles
The initial aim of the study was to verify or refute the claims
of Krontiris and colleagues (Krontiris 1986) that patients with
cancer (specifically breast cancer) show an increased incidence of
rare Harvey-ras alleles in their constitutional (i.e. blood) DNA.
At the same time DNA was extracted from a series of breast tumours to
see if there were detectable somatic changes at the Harvey ras locus.
The four common Bam HI Harvey ras alleles are seen in Fig. 5.
a4
a2
Fig 5 Alleles of c-Ha-ras (Bam HI digests) from four placental DNA
samples. The left hand track of this Southern blot contains a
'doublet' of allele A, and the rare variant A^'.
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In common with other authors the restriction fragments are
arbitrarily indexed in ascending order of molecular weight. A1 is
6.9kb, A2 is 7.6kb, A3 is 8.0kb and A4 is 8.3kb. A3 and A4 are
fairly close together and as is clear from Figure 1, the difference
in molecular weight between the common A1 allele and its rare variant
Al' is small. We have routinely run these gels for 48 hours with
the buffer being pumped through ice to give clear, repeatable
resolution of these fragments. We have also extracted DNA from a
breast cancer cell line MCF 7, which is homozygous for a rare Al'
allele, as seen in Figure 6.
T P P P
i
Fig 6 Bam HI digests of DNA extracted from MCF 7 cells (T) with
three placental controls (P) probed with c-Ha-ras.
68
We run standard placental samples containing 4 common alleles on
both sides of each gel, and so we are confident that our system will
reproducibly detect rare alleles. Table 1 shows the relative
frequencies of these alleles in 100 breast cancer patients and 100
placentae.
Table 1
The distribution of Bam HI alleles at the Harvey ras locus in
100 breast cancer patients and 100 placentae
100 Breast cancer patients 100 Placentae





126 63.0 135 67.5
25 12.5 27 13.5
23 11.5 19 9.5
19 9.5 15 7.5
7 3.5 4 2.0
In agreement with other authors, rare alleles can be identified
in the normal population, but there is no significant difference
between breast cancer patients and controls in the frequencies of
these rare alleles; nor is there any shift in the distribution of
common alleles between the two groups.
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Harvey ras allelic loss in tumour DNA
While completing the analysis on Section 1, we noted that in
several of the heterozygous tumours, 1 allelic band was much darker
than the other as illustrated in Figure 7.
P P P T P P P
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Fig 7 Bam HI digests of DNA extracted from a breast tumour (T) with
placental controls (P) as before probed with c-Ha-ras. Note that
the lower tumour allele band (Aj) is much less dense than the upper
(a3 ) *
The relative intensities of the bands in different gel tracks
suggested that there had been no gross amplification of a Harvey ras
gene in any of the tumours. An alternative explanation for the
evident imbalance between the two alleles in some DNA preparations is
that the tumour cells have lost one allele and the fainter band seen
results from contamination of the tumour sample by non-neoplatic
cells. This was supported by comparing paired tumour DNA and white
blood cell DNA samples from the same patient, as seen in Fig. 8.
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Fig 8 Bam HI digests of tumour (T) and blood leukocyte (B) DNA from
the same patient, probed with c-Ha-ras and compared with three
placental controls (P). Note that alleles and A3 are of equal
intensity in B, but allele Aj is almost absent from the tumour
sample.
T B P P P
However, if there was minimal infiltration by non-neoplastic
cells, the tumour sample might appear homozygous i.e. one allelic
band was lost so completely that it was not visible. In our study,
61 tumours were heterozygous of which 10 had clear loss of one
allele. 39 tumours were "apparently" homozygous, but when we
examined the white blood cell DNA in these individuals 4 were con¬
stitutionally heterozygous. The total collection of tumours could
be subdivided as follows.
1 No allelic loss at the Harvey-ras locus - 51 tumours.
2 Loss of one allele - 14 tumours.
3 Uninformative, because the patient was constitutionally
homozygous - 35 tumours.
Thus, 14 out of 65 informative tumours have lost one Harvey-ras
allele.
Clinico-pathological associations of Harvey ras allelic loss
There was no preferential loss or retention of any of the four
common alleles, and our present analysis does not allow us to
determine the maternal or paternal derivation of a lost allele.
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In an analysis of the 65 tumours informative at the Harvey-ras
locus, we found no significant correlation between allelic loss and
menopausal status, age at presentation or history of an affected
first degree relative.
However, as shown in Table 2 there was a significant correlation
between loss of a Harvey-ras allele and paucity of oestrogen receptor
protein, absence of oestrogen receptor being a well-recognised index
of poor prognosis (Croton 1981; Moore 1983; Williams 1987; Shek
1987).
TABLE 2 - RELATIONSHIP BETWEEN LOSS OF A HARVEY RAS ALLELE
AND OESTROGEN RECEPTOR LEVEL IN 61 BREAST TUMOURS
ER poor/-veER moderate/rich
^20fmol/mg protein > 20fmol/mg protein (20)
Allelic Loss 8 6
No Allelic Loss 10 37
p= 0.02 by Fishers exact test
4 samples from patients on Tamoxifen produced a doubtful assay and
were therefore excluded.
There was also a significant correlation between tumour size and
allelic loss as shown in Figure 9.
HARVEY RAS ALLELIC LOSS & PATHOLOGICAL TUMOUR SIZE
No. Loss n = 51
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Tumour size in m.m.
Fig 9 Distribution of primary tumour size (greatest diameter in mm)
in relation to Ha-ras allele status.
TABLE 2a
Ras loss No Ras loss Unknown




2/11 18/45 9 3.2
2/14 12/51 0 0.84
2/14 12/51 0 0.84
All values are insignificant by the test, with Yates correction, if
appropriate.
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There was no significant correlation between allelic loss and
pathological lymph node involvement, vascular invasion, lymphatic
invasion, or histological type of tumour.
Mechanism and extent of loss of a Harvey ras allele
Several mechanisms could be responsible for the finding that 21%
of primary breast carcinomas have lost one Harvey-ras allele. These
include a deletion, mitotic recombination, or loss of a whole
chromosome as explained in the Introduction (p7). In an attempt to
clarify which mechanism is most likely to have occurred in our
material, we have examined several other loci on chromosome 11. The
numbers involved in this part of the study are smaller, as we had to
use DNA from patients' lymphoblastoid cell lines for the multiple
digestions required.
We have examined 3 loci on llq as detailed in Table 3.
TABLE 3
Gene or Desig- Localis- Restric- No No No
probe nation ation tion Enz Ref Examined Informative Lost
APOA 1 pBAl llq23 Sac I (1) 20 0
Int2 pSS6 llql3 Bam HI (2) 20 0





Two loci were completely uninformative in our patients, but the
third, Pepsinogen, provided good evidence that a whole copy of
chromosome 11 has not been lost in these tumours, and we therefore
turned to a more detailed analysis of lip.








Restric- No No No
tion Enz Ref Examined Informative Lost
g-globin Pst- g llpl5 Bam Hi *1 20 12 4
PTH pEB 3 lip 13-15 Pst 1 *2 19 9 5
Calcitonin phT-B3 lip 15-4 Taq 1 *3 20 4 2
FSH- g pRS 1-2 lip 13 Hind III *4,5 22 8 3
D11S49 Apll F9 lip 13 Bgl 1 *6,7 19 16 5
Total 49 19
*1 - Deisseroth et al 1978
*2 - Naylor et al 1982
*3 - Hoppener et al 1984
*4,5 - Glaser et al 1985; Watkins et al 1985
*6,7 - Porteous et al 1987; Boyd et al 1989
Representative autoradiographs from some of these probes are
illustrated in Fig 10.
C T C T C T
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I
Fig 10 Paired digestions of DNA from tumour (T) and lymphoblastoid
cell lines (C) from 3 patients, probed with (i) PTH (pSTl) (ii) g-
globin (Bam HI) (iii) Calcitonin (Taq). Note loss of one allele in
each tumour.
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Heterozygosity was found on a total of 49 occasions and the
corresponding tumours had lost an allele in 19 cases (38.8%). 19
tumour/cell line pairs have been fully characterised for all five
loci, as tabulated in detail below.
TABLE 5
DETAILS OF ALLELIC LOSSES ON lip IN 19 TUMOUR/CELL LINE PAIRS
Tumour/
cell line pair Ha-Ras g-globin PTH Calcit fsh-3 XP11F5
1 a- u a- a- a- a-
2 a- a- u u a- u
3 a- u u a- u u
4 a- u u ab ab u
5 a- u u u u ab
6 a- u u u u ab
7 a- ab u u u ab
8 a- ab a- u a- ab
9 ab u u u u a-
10 ab u u u u ab
11 ab ab ab u u ab
12 ab ab ab u u ab
13 u ab u u ab a-
14 u ab a- u u a-
15 u u a- u u a-
16 u ab u u u ab
17 u u ab u ab u
18 u a— u u u ab
19 u a- u u u ab
a = informative and lost
ab = informative, not lost
u = uninformative (constitutionally homozygous).
Of the 19 pairs, 12 were informative for Harvey-ras, of which 8
showed allele loss (1-8). Three of the 8 (1,2,3) showed loss at all
informative loci on lip consistent with loss by mitotic recombination
below lip 13.
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Four of the 8 (4,5,6,7) were uninformative or showed no loss at
any of the other lip loci, while the remaining tumour (8) showed
allele loss at Harvey-ras, PTH and FSH B, but not Dll 549 and more
significantly beta-globin. This suggests that a double event
(involving inversion or deletion and mitotic recombination) has taken
place in this tumour as the chromosomal localisation of Harvey-ras
PTH and beta-globin relative to each other is well-established by
physical and genetic linkage analysis (Naylor 1982; Desseroth 1978).
In one of the 4 tumours (9) which were informative for ras, but
showed no loss, there was loss of the llpl3 marker Dll S49, and
similarly amongst the 7 tumours uninformative for ras (13-19) we
found allelic loss at Dll S49 in one (13), where FSH B and beta-
globin were both informative but showed no loss. Two further
tumours showed loss at Dll S49 and also at PTH with intervening loci
being uninformative (14,15).
This detailed analysis demonstrates that no specific locus or
region was ubiquitously lost.
Of these 19 tumour/cell line pairs, 10 (53%) had lost an allele
at one or more locus, (excluding Harvey-ras) on lip. This figure
must be treated with caution, as 8 out of the 19 pairs were known to
have lost Harvey-ras, and the data in Section 2 suggests Harvey-ras
loss in 21% of primary tumours. However, it is clear that there is
a substantial frequency of DNA lesions on lip in primary breast
tumours.
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Specificity of allelic loss on lip
In order to assess whether allelic loss is a generalised
phenomenon throughout the genome, we have examined several other loci
using probes that are highly polymorphic, and therefore likely to be
informative in a high percentage of individuals, as detailed in Table
6 with representative autoradiographs below.
TABLE 6
Gene or Desig¬ Localis¬ Restric¬ No No No
probe nation ation tion Enz Ref* Examined Informative Lost
Pepsin¬ pH PEP llq 12 EcoR I 1,2 24 20 0
ogen
Erb A pHcA2 17q21.3 Bam HI 3 20 11 0
MHC pll-B-4 6q21.3 EcoR 1 4 21 21 0
Class II
XMS8 D8 S43 5q34qter Hinf 1 5,6 18 15 1
Total 67 1
Adding in the data on llq from the previous section we find loss
in only one of 67 informative loci, so it is not a generalised
phenomenon. As a continuation of this work, we also used the mini-
satellite locus-specific probe, YNZ 22, mapping to 17p, with the
restriction enzyme MSP I (as detailed in the Methods section).
The resulting autoradiographs were very complex, with a large
number of bands, although it did appear that several tumours had lost
one or more bands. Whether this was due to incomplete digestion was
unclear. Examining a panel of normal placental DNAs, confirmed
that, although it was definitely possible to identify different
genotypes, it was very difficult to identify allelic bands as seen in
Fig 12. A much more readily analyzable pattern was produced by
using a different restriction enzyme, Taq I and it became clear that
loss of the YNZ 22 locus on 17p was common in breast tumours.
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Fig 11 Paired digestions of DNA from tumour (T) and lymphoblastoid
cell lines (C) from i) one patient probed with PGA (Eco Rl) and ii)
Three patients probed with AMS8 (Hinf 1). Note that none of the
tumours have lost an allele.







Fig 12 Mspl digestions of DNA from 5 placental samples probed with
YNZ 22 showing the complex binding pattern, although different
genotypes can be recognised.
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Loss of a YNZ 22 allele in tumour DNA
A series of fifty tumour/cell lymphoblastoid lines or tumour/
white blood cell pairs was examined from forty-five individuals,
three patients having two discrete tumours, and one having three.
Twelve individuals were constitutionally homozygous, and of 38
heterozygous tumours there was allelic loss in 23 (61%). Two
informative areas on 17q were also examined, as seen in the table
below, demonstrating that the majority of tumours have not lost a
whole copy of chromosome 17.
TABLE 7
No of
Chromo- Gene or Restri- No of No of tumours
somal probe tion Tumours Patients showing
location enzymes examined heterozygous loss
17p 13.3 YNZ 22.1 Taq 1 50 38 23 (61%)
17q 21.3 Erb A2 Bam HI 20 11 0 )
(pHe A2) ) 3_3Z
17q 25 pTHH59 Taq 1 35 19 1*)
*Uninformative for 17p.
In two instances separate (but coincident) tumours from the same
patient differed in respect of YNZ 22 allele status (as seen in Fig
13).
Fig 13 Taq 1 digestion of tumour (T) and leucocyte (B) DNA from 3
patients probed with YN2 22. The right hand trio shows allelic loss
in one tumour, but probable retention in the other.
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Of the fourteen tumours showing loss of a Harvey ras allele,
ten (71%) had lost a YNZ 22 allele - evidence that the two events are
o
neither mutually exclusive nor preferentially associated using the X
test on tumours informative for both loci.
In keeping with that observation, loss of a YNZ 22 allele was
not correlated with low oestrogen receptor protein level, metastatic
lymph node involvement or family history as tabulated below (the 12
uninformative individuals for YNZ 22 are excluded).
TABLE 8
Association between loss of a YNZ 22 allele and
oestrogen receptor content
ER +ve ER -ve
( ^20fmol/nig) (>20fmol/mg)
YNZ 22 loss





4 tumours excluded X2 = 3.24 N.S.
TABLE 9
Association between loss of a YNZ 22 allele
and metastatic lymph node involvement
Node +ve Node -ve
YNZ 22 loss





All tumours included X2 =0.76 N.S.
TABLE 10
Association between loss of a YNZ 22 allele and family history
(one or more first degree relatives affected with breast cancer)
+ve Family History No Family History
YNZ 22 loss 2 16
YNZ 22 no loss 3 10
Individuals with tumours with different genotypes excluded.
X2 = 1.06 N.S.
There was no association between YNZ allelic loss and tumour size or
mean age at presentation.
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7 YMZ 22 ALLELES IN A LARGE KINDRED WITH FAMILIAL BREAST CANCER
A large kindred with a high incidence of breast cancer was
identified and the pedigree extended and verified. The full
pedigree is illustrated in Figure 14.
Fig 14 Pedigree of a family with a high incidence of breast cancer.
Note 7 individuals with breast cancer out of 16 over the age of 30.
Of this kindred seven females had histologically proven breast
cancer (3 bilateral) out of 16 at risk (discounting those under 30
years old) in 3 generations. Age at diagnosis ranged from 31 to 46
years. Inheritance followed a pattern consistent with an autosomal
dominant trait with incomplete penetrance. There was no apparent
excess of other cancers.
Among the affected individuals was a pair of monozygotic twins,
and another pair of dizygotic twins. The Taq I YNZ 22 genotypes of
both affected and unaffected individuals in this kindred, either
directly ascertained or inferred are illustrated in Figure 15.
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For this kindred, the following lod scores were calculated by
Dr J F Clayton, using a programme derived from a MOLL/SITU package as
previously described (Clayton 1986). Calculating these lod scores
involved making assumptions about:
The mode of segregation of the disease gene, the local disease
gene frequency, and the local disease gene penetrance, as made by
Williams in a Danish complex segregation analysis (Williams et al
1984).
(1) Assume a very rare gene with very low penetrance:- lod score at
0 recombination = 1.8.
(2) Assume a rare gene with 60% penetrance in an 80 year old
carrier:- lod score at 0 recombination = 1.06.
(3) Assume a fairly common gene with 60% penetrance in an 80 year
old carrier:- lod score at 0 recombination =0.68.
While these results fall short of definitive proof that YNZ 22
alleles are linked to susceptibility to breast cancer, they are
highly suggestive.
15TaqIYNZ22genotypesoftheimportantindividualfamilyllustr tedFig4.S lidymbo representindividualswithbr ascanc r
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DISCUSSION
Frequency of rare Bam HI Harvey ras alleles
1 These results, in agreement with several published studies
(Krontiris 1985; Thein 1986, Heighway 1986) demonstrate that rare
Ha-ras alleles can be identified in the normal population. However,
we have found no evidence for an increased frequency of rare alleles
in breast cancer patients, contradicting both Krontiris' initial
report (1985), and the findings of a subsequent larger series
(Lidereau 1986) in which rare alleles were identified in 41% of
breast cancer patients.
As mentioned in the introduction (p26), it was essential to
substantiate or refute Krontiris' initial report, by performing large
studies on patients with a single tumour type. Several of these
have now been published, by other groups.
Thein (1986) reported rare alleles in 2.8% of patients with
myelodysplastic syndrome compared to 4.8% in controls. Gerhard
(1987) reported 4% of melanoma patients had rare alleles compared to
6% in controls, confirmed by Hayward et al (1988). Heighway (1986)
reported 5-7% in lung cancers, compared to 4% in controls.
Ceccherini-Nelli (1987) reported rare Taq I alleles in 4% of colonic
adenocarcinoma patients compared to 2.5% in controls, supported by a
carefully controlled study (Wyllie 1988) of Bam HI and Ava II alleles
in colorectal cancer patients. This last study highlights the need
for considering all sources of artefact in the Southern blots. The
authors found that loading the correct weight of DNA in each slot was
critical, and also noted that in several tumour DNA samples partial
degradation of the DNA during storage resulted in the identification
of apparently "rare" alleles. The studies reported by Lidereau et
al (1986) in breast cancer patients were almost all performed on
tumour DNA, from patients, whereas white blood cell DNA was used for
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controls. Our carefully controlled study, initially reported in
early 1987 (Mackay 1987), using placental markers on both sides of
the gel, and comparing white blood cell DNA to tumour DNA from the
same patient in any cases of doubt, as recommended by Wyllie et al
(1988) support this interpretation, and unequivocally demonstrate
that rare Harvey-ras alleles are not increased in breast cancer
patients. This agrees with a subsequent, smaller study, reported by
White (1988).
Wyllie's conclusions are further supported by Hayward's study
(1988), as he looked at either white blood cell DNA or cell line DNA
from patients and relatives with melanoma and Wilm's tumour. He
also examined DNA from transitional cell bladder tumours and reported
a significant percentage of rare alleles only in bladder carcinoma,
the one group in which the analysis was performed on tumour tissue.
Radice (1987) digested white blood cell DNA from 55 melanoma
patients, with Taq I. He identified an additional polymorphism,
separate from that detected by Bam HI or MSP/HPA, which had been
previously reported (Pierrotti 1986). This Taq 1 polymorphism was
present in 18% of melanoma patients, significantly greater than in
his control population (6%). In the absence of other studies
examining this particular polymorphism the significance of his
observation remains unclear.
Heighway originally reported (1986) a preponderance of the
common Bam HI A4 allele in non-small cell carcinoma of the lung, and
Wyllie (1988) reported a preponderance of the two larger common
alleles A3 and A4 in colorectal cancer.
In agreement with White et al (1988) we found no significant
difference in the frequency of any of the common alleles in breast
cancer patients.
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Harvey ras allelic loss in tumour DNA
Our finding of loss of a Harvey-ras allele in 14 of 65
informative tumours (21.5%), is in good agreement with the small
study of Yokota (1986) and the larger study of Theillet (1986). The
fact that there was no preferential loss of larger alleles, and that
allelic loss was found in only 1 of 67 informative loci outside lip,
make it very unlikely that this finding was an artefact caused by
degradation of the tumour DNA as mentioned by Wyllie (1988). The
significant correlations between Harvey ras allelic loss and paucity
of oestrogen receptor protein, and between Harvey-ras loss and larger
tumours, contrasting with the absence of any significant correlation
between Harvey-ras allelic loss and regional lymph node metastases,
all agree with the findings of Theillet et al (1987). They
concluded that Harvey-ras allelic loss was significantly linked to
parameters of tumour aggressiveness on the basis of observed
correlations between Harvey-ras allelic loss and paucity of oestrogen
receptor protein, histological grade, and early occurrence of distant
metastases. Their studies were performed on tumour samples stored
for up to 7 years. As our analysis was done prospectively, we will
have to wait for data on disease free interval and 5 year survival,
before we can comment authoritatively on the prognostic importance of
Harvey ras allele loss.
Our detailed data on 19 tumour/cell line pairs, fully character¬
ised for 5 loci on lip outwith the Harvey ras locus, presented in
Table 5, suggest that it is likely to be a locus on lip near Harvey-
ras, rather than Harvey-ras itself which is of importance in breast
cancer. These data are compatible with simple mitotic recombination
below llpl3 in some tumours, though more complex mechanisms may be
involved in other tumours. This refutes the smaller study of Ali et
al (1987) who suggest the existence of a putative locus between the
beta-globin and PTH loci, which must be deleted en route to full¬
blown malignancy. This issue will only be fully resolved by a
larger study, examining lip in more detail, and making use of the
growing number of highly polymorphic DNA sequences currently being
characterised to study the WAGR locus (Porteous 1987; Boyd 1988).
However, there has clearly been a substantial frequency of DNA
lesions within the short arm of chromosome 11 in our tumour material,
lending support to the localisation of a putative tumour suppressor
gene in breast cancer, to lip (Mackay 1988a).
Involvement of 17p in familial and sporadic breast cancer
A note of caution must be sounded when drawing conclusions from
genetic lesions found in tumour tissue. Biochemical and cytogenetic
evidence has been available for many years to show that malignant
cells tend to accumulate multiple aberrations in their DNA, including
gene deletions (Povey 1980; Sandberg 1980). Recent studies using
highly polymorphic probes of unknown locus specificity have confirmed
these findings (Thein 1987), and allelic loss on 13q has been demon¬
strated in a small number of ductal breast cancers (Lundberg 1987).
It is very unlikely that all these aberrations contribute to the
malignant state.
The last part of our study neatly side-steps this problem, and
provides definite experimental evidence supporting the theoretical
strategy of attempting to identify DNA sequences consistently lost in
tumour tissue, as outlined in the introduction (p8-10, 23,24).
Our finding that 61% of informative breast tumours have lost one
Taq I YNZ 22 allele, coupled with the tight linkage demonstrated
between the same locus and the trait of susceptibility to develop
hereditary breast cancer in one large kindred, appears analogous to
the findings in retinoblastoma outlined, at length, in the
Introduction (p6-10).
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These findings strongly suggest that 17p plays an important role
in the aetiology of breast cancer. Accepting that carcinogenesis is
a multi-stage process, we do not yet know whether 17p is involved in
the early or late stages.
In two individuals, who had two discrete tumours, we have
identified YNZ 22 allelic loss in only one of each pair, suggesting
that 17p involvement is a "later" event which is in broad agreement
with Fearon's conclusion that in colonic carcinoma (Fearon 1987),
loss of sequences on 17p is a late event in the progression from
adenoma to carcinoma. This is the first report of 17p deletions in
sporadic breast cancer (Mackay 1988b) confirmed by Devilee et al
(1989) but there have been no previous reports of linkage to 17p
markers in familial breast cancer.
Our figure of YNZ 22 allelic loss in 61% of primary breast
tumours might well be an underestimate, as several of the tumour DNA
samples, showed a suspicious inequality in the intensity of the two
autoradiographic bands, which although not scored as allelic loss,
suggests that there may be a subpopulation of tumour cells that has
undergone hemizygotisation, and that the true figure is closer to
76%, reported for colonic carcinoma (Fearon 1987).
We used YNZ 22 because although anonymous i.e. untranslated, it
is highly polymorphic and therefore very informative (Nakamura 1988),
but these findings do inevitably raise the question, "which gene on
17p is actually involved in breast cancer?"
One of the strongest candidates is p53, which has recently been
mapped to 17pl3, the same band as YNZ 22 (Van Tuinen 1988; Cohen-
Haguenauer 1988). This gene has been fully discussed in the
Introduction (p20-22), but a couple of facts bear repetition. It is
expressed at a high level in 15% of aggressive primary breast tumours
(Cattoretti 1988) and studies in the mouse have suggested that
located upstream of a promoter sequence, there is a negative
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regulatory sequence (Bienz-Tadmar 1985). It is quite possible,
considering the other facts known about the activity of p53, that
this negative regulatory element is, in fact, a "tumour suppressor
gene". Obviously, further mapping studies are required to eluc¬
idate this point fully.
The significance and implications of 17p involvement
Our lack of knowledge means that several assumptions (e.g. local
disease gene frequency, disease gene penetrance) have to be made in
calculating the lod score. A lod score of 1.8 calculated by Dr J F
Clayton, on the basis of Williams and Anderson's (1984) data, is
encouragingly high for a preliminary study. Given these
constraints, it is likely that statistical significance will only be
reached by a lod score of well over 3. As explained in the intro¬
duction (p26-31), the next step is to examine several other families,
with clear transmission of the susceptibility trait. This will in¬
evitably involve collaboration with other large breast cancer units
throughout the country.
If our preliminary findings are confirmed, we will then be able
to screen relatives of patients with a strong family history of
breast cancer. Because the disease gene clearly demonstrates in¬
complete penetrance, we would not be able to say definitively that
any individual was going to develop breast cancer, but we would be
able to identify individuals who were not at increased risk of
developing hereditary breast cancer.
Hereditary, as opposed to sporadic, breast cancer, only
comprises a small percentage (18%) (Lynch 1984), of the total pool of
breast cancer, and so these findings are unlikely to make a large
impact on population-based screening. They will allow us to
identify a subpopulation of individuals, previously thought to be "at
high risk", due to family history, who are in fact not at such high
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risk, although of course, we will be unable to determine the risk of
their developing sporadic breast cancer.
The second major implication of these findings, is that we now
know the chromosomal localisation of a gene likely to be of
importance in both breast and colonic carcinoma. The finding that
loss of a region on lip is not associated with loss of YNZ 22 on 17p
is further evidence for the multi-stage nature of human carcino¬
genesis. Vogelstein (1988) has proposed a sequence of events in the
genesis of colonic cancer and it is very likely that a similar
sequence will be involved in the genesis of breast cancer.
Molecular genetics is at the stage of identifying individual com¬
ponents of this multifactorial process, and this work has made a
significant contribution to the identification of two of these com¬
ponents .
Further progress will only be made by pinpointing the actual
genes involved on lip and 17p, and understanding how they interact in
the process of evolution and progression of malignancy.
This knowledge will almost certainly open up new opportunities
for prevention and treatment of breast cancer.
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ALLELE LOSS ON SHORT ARM OF
CHROMOSOME 17 IN BREAST CANCERS
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Summary Tumour and blood leucocyte DNA from a
consecutive series of patients with primary
breast cancer was probed to detect deletions at six
polymorphic loci in tumour tissue. The highest frequencyof
allele loss (61%) was found with the probe YNZ22, which
detects a sequence on the short arm of chromosome 17 (at
pi 3.3). The previously reported loss of alleles at the Harvey
ras locus (llpl4) in about 20% of breast tumours was
confirmed. The putative breast tumour suppressor gene on
17pmay be the same as that already noted for colon and lung
cancers and it is suggested that deletion of this gene is one of
a cumulative series of lesions involving genetic changes in
the evolution of breast cancer. The findings identify
chromosome 17p as a candidate region for linkage studies in
breast cancer families.
Introduction
There is growing recognition of the importance of
suppressor genes ("anti-oncogenes") in human cancers.lJ1
These genes are recognised by their inactivation or loss
(usually detected as deletion of the chromosome region
bearing one copy) in a substantial proportion of tumours ofa
given histological type. The inactivation of a series of
tumour suppressor genes and the activation of one or more
oncogenes appear to be cumulative steps on the route to
overtmalignancy in the case ofcolon cancer,5 and this model
is probably valid for other human tumours.6
Heritable lesions affecting several tumour suppressor
genes (some still putative) seem to determine genetic
susceptibility to malignancies behaving as autosomal
dominant disorders with variable penetrance. This pattern
of inheritance is believed to underlie familial aggregations of
breast cancer that have been recognised for over a century,7
but as yet there are no data on the location of a predisposing
gene or genes.8 11 The present study was designed to locate
tumour suppressor genes involved in sporadic breast cancer
and which would be candidates for genetic linkage studies in
familial cases.
Patients and Methods
Fresh tissue was obtained from 100. consecutive resectable
primary breast tumours removed at operation from patients
presenting to the breast cancer clinic of the Edinburgh University
Department of Clinical Surgery. All tumours were less than 5 cm
diameter at diagnosis and no patient had received radiotherapy or
chemotherapy (other than the anti-oestrogen tamoxifen) before
surgery. A blood sample was also obtained from each patient and
DNA was extracted from both tumour tissue and blood leucocytes
by conventionalmethods.12 In many instances a lymphoblastoid cell
line was established from the blood lymphocytes, by transformation
with Epstein-Barr virus, to provide a renewable source of the
patient's constitutional DNA.
10 pg samples of DNA from tumours, blood leucocytes, and
lymphoblastoid cell lines were digested with each of the restriction
enzymes listed in the table. The digests were electrophoresed
through 0-8% agarose, transferred to nylon membranes (Hybond,
Amersham), and probed with the seven sequences also listed in the
table. Probes were previously labelled with 12P dCTP or dTTP to a
specific activity of at least 5 x 107 cpm/pg by nick translation.13
Filters were washed at 65°C with 01 * SSC(15 mmol/1 NaCl, 1-5
mmol/1 sodium citrate, 0-1% sodium pyrophosphate, 01% sodium
dodecylsulphate) and exposed to Kodak 'X-Ar' film at — 70°C for
7-14 days with intensifying screens.
Not every tumour has been genotyped with all seven probes
because the quantity of tumour DNA is limited and must be
conserved for detailed mapping studies that will follow this type of
screening.
Results
As shown in the table, there was little or no evidence of
gene deletion in tumour tissue for four of the six
chromosomal regions examined (5q34, 6p21, llql2, and
17q21-25). We did confirm the previously reported loss ofa
Harvey ras allele (1 lp 1.4) in about 20% of tumours15-16 and
this observation has been discussed in detail elsewhere.17
The most striking finding, however, was that 23 of the 38
tumours from patients constitutionally heterozygous at the
17p locus defined by the probe YNZ2218 had undergone
partial or complete loss ofone allele (figure). That this loss is
confined to a region of the short arm of chromosome 17 and
does not reflect loss of a complete chromosome is evident
from the retention ofheterozygosity at 17q in those rumours
informative for pHeA2 and PTHH59. In two instances
separate (but coincident) tumours from the same patient
differed in respect ofYNZ22 allele status (figure). Several of
the tumour DNA samples that were scored as having no
allele loss nevertheless showed a suspicious inequality in the
intensity of the two YNZ22 Taq 1 autoradiographic bands,
suggesting the presence in the tumour mass of a population
of cells that had indeed undergone hemizygotisation; so the
figure of 61% of primary breast tumours showing
involvement of a 17p locus is almost certainly an
underestimate. Of the fourteen tumours showing loss of a
c-Ha-ras allele (lip) ten (71%) had also lost a YNZ22
allele—evidence that the two events are neither mutually
exclusive nor preferentially associated.
In keeping with that observation, we found that loss of a
YNZ 22 allele was not correlated with such adverse
prognostic indices as low oestrogen receptor level or
NUMBERS OF BREAST CANCERS SHOWING SPECIFIC ALLELE LOSS IN
PATIENTS CONSTITUTIONALLY HETEROZYGOUS FOR VARIOUS
DNA MARKERS
No of
Gene or No of No of tumours
probe Restr tumours patients showing
Chromosome (ref 14) enzyme examined heterozygous loss
5q34 XM.S8
(D5S43)




EcoRI 21 21 0
1 lpl.4 Ha-ras
(pEj)




EcoRI 24 20 0




BamHl 20 11 01>(3-3%)
17q25 pTHH59 Taql 35 19 »*J
*Uninformative for 17p.
The DNA probes listed were generously supplied by the following:
Prof Alec Jeffreys; P11B4, Dr Dan Larhammar; pEj, Dr Chiah Shih;
pHPEP, Dr R Thomas Taggart; YNZ 22 and pTHH 59, Dr Yusuke
Nakamura; and pHeA2, Dr Matts Jansson.
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Audioradiograph of tumour (T) and blood leucocyte (B) DNA from
three breast cancer patients, digested with Taq 1 and Southern
blotted with labelled probe YNZ22.
Tumour tissue from the patient in the left hand panel shows a marked
reduction in intensity of the lower allele, indicating either that the tumour is a
mosaic of heterozygous and hemizygous malignant cells or that there is a
substantial admixture of heterozygous non-malignant cells (stroma,
infiltrating lymphocytes,&c) in a hemizygous tumour. The tumour sample in
the centre panel shows complete absence of one YNZ22 allele while the
patient whose samples are shown in the right hand panel had two discrete
primary tumours, one ofwhich retained both YNZ22 alleles, the other being
hemizygous. Note that, as expected for a polymorphic system, some allelic
bands are common to two or more patients. In the material studied there is no
apparent tendency for loss of any particular allele.
increased size of tumour at presentation, whereas loss of a
c-Ha-ras allele correlated with both.17
Discussion
This is the first report of an association between loss of
sequences on chromosome 17p and breast cancer.
Involvement of this region has, however, been described in
colorectal carcinoma,5'19'20 in lung cancer,21 and in
osteosarcoma.22 In the case ofcolon cancer, there is evidence
for cumulative genetic lesions leading to overt malignancy.5
These include inactivation of putative tumour suppressor
genes on 5q, 17p, and 18q and activation of one of the ras
family of oncogenes. Separate studies of lung cancer have
identified probable tumour suppressor genes on 3p, 13q,
and 17p while in breast tumours there is now substantial
evidence to implicate corresponding sequences on 1 lp, 13q,
and 17p as well as amplification of the Erb B2/neu onco¬
gene.15-1723-25 In addition, cytogenetic analyses of near-
diploid primary breast tumour cells have revealed a variety
of chromosome deletions, translocations, and complete
losses with particularly frequent involvement of
chromosome 1 and the long arm of chromosome 11 at
ql3.2fr28 All of these findings are consistent with the
substantial body ofevidence indicating that an accumulation
of genetic events is required for the evolution of frank
malignancy. Our observations of disparity in terms of 17p
allele loss between two breast tumours occurring
simultaneously in the same patientmay imply that loss ofthe
putative tumour suppressor gene at that locus need not be an
early event in the evolution of breast cancer, but it should
also be borne in mind that the crucial deletion or inactivation
of a gene on 17p must be close to, but may not always
include, the YNZ 22 locus. Heritable cancer syndromes
behaving as autosomal dominant disorders have been shown
to be associated with lesions on 3p (renal cell carcinoma), 5q
(familial adenomatous polyposis), 10 (multiple endocrine
neoplasia type 2), 11 q (multiple endocrine neoplasia type 1),
lip (Wilms' tumour), and 13q (retinoblastoma),4 though
only in the case of the 13q locus is there direct evidence that
precisely the same DNA sequence is implicated in the
inherited condition and in sporadic lung and breast
tumours.232429 The present findings identify the short arm
of chromosome 17 as a candidate region for localisation of a
gene conferring increased susceptibility to breast cancer.
The fact that the same region has also been implicated in
sporadic tumours of colon and lung is of particular interest
in view of the extensive evidence that "breast cancer
families" commonly show, in addition, an excess of other
types of tumour.71011
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Partial deletion of chromosome lip in breast cancer correlates with
size of primary tumour and oestrogen receptor level
J. Mackay1, P.A. Elder1, D.J. Porteous1, C.M. Steel1, R.A. Hawkins2, J.J. Going3
& U. Chetty2
1MRC Clinical and Population Cytogenetics Unit, Western General Hospital; 2 University Department of Clinical Surgery,
Royal Infirmary of Edinburgh and 3Department of Pathology, Edinburgh University Medical School, Edinburgh, UK.
Summary In a study of DNAs from 100 breast cancer patients and 100 controls, there were no differences in
the frequencies of common or rare alleles at the Harvey ras (c-Ha-ro.r) locus on chromosome 11. However,
one Ha-ras allele was deleted from the tumour DNA in 14 of 65 informative patients. Loss of a Ha-ras allele
correlates with paucity of oestrogen receptor protein and with increased tumour size at presentation, but is
not associated with microscopic evidence of lymph node invasion. The findings on Ha-ras and other
informative loci are consistent with the possibility that a tumour suppressor gene involved in the early stages
of breast cancer is located on the short arm of chromosome 11.
The human Ha-ras oncogene, homologous to the trans¬
forming sequence of the Harvey murine sarcoma virus, has
been assigned to the short arm of chromosome 11 (McBride
et al., 1982). On the 3' side of the gene lies a non-coding
region made up of a variable number of repeated sub-units
(Capon et al., 1983). Digestion with the restriction enzyme
Bam HI generates a restriction fragment length poly¬
morphism with 4 common and several rarer alleles. Krontiris
et al. (1985) have reported an increased frequency of rare
alleles in patients with a variety of solid tumours and
haematological malignancies; their series included a small
number of breast cancers. This finding would imply that an
inherited predisposition to cancer is linked to alleles at the
Ha-ras locus. Several subsequent studies have sought to test
Krontiris' hypothesis as applied to lung cancer (Heighway et
al., 1986), myelodysplasia (Thein el al., 1986), colonic adeno¬
carcinoma (Ceccherini-Nelli et al., 1987), familial melanoma
(Gerhard et al., 1987; Hayward et al., 1988) and breast
cancer (Lidereau et al., 1986). Only in the last two of these
has supporting evidence been forthcoming (Lidereau et al.,
1986; Hayward et al., 1988). However one group has
recorded that a proportion of breast tumours, from patients
constitutionally heterozygous at the Ha-ras locus, express
only one allele or show a marked disparity in the intensity of
the two allelic bands, suggesting that most or all of the
tumour cells have undergone loss of a part of chromosome
lip (Theillet et al., 1986; Ali et al., 1987). Reduction to
homo- (or hemi-) zygosity at specific genetic loci was
recognised initially in retinoblastoma and subsequently in
several other tumours (Knudson, 1971; 1985). The loci
involved are believed to be sites of tumour suppressor genes
or 'anti-oncogenes' which are relevant both to somatic events
giving rise to sporadic tumours and to genetic predisposition
to cancers (Lancet, 1988). In view of the potential impor¬
tance of these issues for breast cancer screening programmes
we have undertaken a survey of Ha-rai alleles in a cohort of
100 breast cancer patients.
Patients and methods
Tumour and venous blood samples have been collected from
100 consecutive patients with histologically proven breast
cancer, prior to any treatment (apart from the anti-oestrogen
tamoxifen). All patients had presented with palpable breast
lumps and were referred by their general practitioners to the
breast clinic in the Royal Infirmary of Edinburgh. Patients
Correspondence: J. Mackay.
Received 11 May 1988; and in revised form, 11 July 1988.
with T4 tumours or with distant metastases at presentation,
were excluded, as they are usually treated by chemotherapy
in the first instance. The surgical procedures performed were
either modified Patey mastectomy with axillary clearance, or
wide local excision with axillary lymph node sampling. The
resected specimen was immediately examined by the patholo¬
gist, tumour diameter measured in mm, and blocks taken for
histological examination and for oestrogen receptor protein
assay. The remainder was frozen on dry ice for later DNA
extraction.
Lymph nodes were processed and examined for micro¬
scopic metastatic invasion. Tumours were classified into
histological types as previously reported (Page & Anderson,
1988). Oestrogen receptor concentration was determined
immediately by a saturation analytical method with sepa¬
ration of free and bound hormone using Dextran-coated
charcoal adsorption as previously described (Hawkins et al.,
1981). Samples from patients who had received Tamoxifen
were rechecked by enzyme immunoassay (Leclercq et al.,
1986). One hundred fresh placental samples have also been
collected to act as a panel of normal controls representative
of the local Edinburgh population. Permanent lymphoid cell
lines were established from many of the blood samples by
transformation in vitro with Epstein Barr virus. DNA was
extracted from tumour and placental tissues and from blood
and lymphoid cell lines (Steel, 1984). Ten pg aliquots of
genomic DNA were digested to completion with Bam HI
(Roberts et al., 1977) (Boehringer, Mannheim GmbH),
electrophoresed through 0.8% agarose, transferred to nylon
membranes (Hybond, Amersham) and hybridised according
to the manufacturer's instructions with the Harvey ras probe
pEj (Shih & Weinberg, 1982), nick translated to a specific
activity of 5 x 107 —1 x 108cpm/rg_1 (Rigby et al., 1977).
After hybridisation, filters were washed at 65°C with
0.1XSSC (15mM Na CI, I.SmM NA3 citrate, 0.1% Na PPi,
0.1% SDS) and exposed to Kodak X-Ar film at — 70°C for
7-14 days, with intensifying screens. Similar procedures were




The four major c-Ha-ras Bam HI alleles At-A4, together
with one rare variant Aj are shown in Figure 1.
Table I shows the relative frequencies of these alleles in
blood and/or lymphoid cell line DNA from 100 breast
cancer patients and in DNA from 100 placentae.
There was no significant difference between breast cancer
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Figure 1 Alleles of c-Ha-ras (Bam HI digests) from four placen¬
tal DNA samples. The left hand track of this Southern Blot
contains a 'doublet' of allele A3 and the rare variant A',.
Table 1 Bam HI alleles of Harvey ras locus
100 Breast
cancer patients 100 Placentae
Number % Number %
a, 126 63.0 135 67.5
a2 25 12.5 27 13.5
a3 23 11.5 19 9.5
a4 19 9.5 15 7.5
Rare alleles3 7 3.5 4 2.0
aAj and A" ... slightly smaller and larger respectively than A,.
patients and controls in the frequencies of rare Harvey ras
alleles; nor was there any shift in the distribution of common
alleles between the two groups.
Allele loss in tumours
Complete or partial loss of a c-Ha-raj allele was established
by comparing paired tumour DNA and white blood cell
DNA samples from the same patients (Figure 2).
The one hundred tumours analysed fall into the following
three categories. No allelic loss at the Ha.-ras locus (51
tumours), loss of one allele (14 tumours) and uninformative,
because the patient was constitutionally homozygous (35
tumours).
There was no preferential loss or retention of any of the
four common alleles and our present analysis does not allow
us to determine the maternal or paternal derivation of a
deleted allele. We found no significant correlation between
allelic loss and menopausal status, age, or history of an
affected first degree relative. However, as shown in Table II,
there was a significant correlation between loss of a Ha-ras
allele and paucity of oestrogen receptor protein; absence of
oestrogen receptor being a well-recognised index of poor




Figure 2 Bam HI digests of tumour (T) and blood leukocyte (B)
DNA from the same patient, probed with c-Ha-ras and com¬
pared with three placental controls. Note that alleles A, and A3
are of equal intensity in B but allele A, is almost absent from
the tumour sample.
There was also a significant correlation between tumour
size and allelic loss as shown in Figure 3.
There was no significant correlation between allelic loss
and pathological lymph node involvement, vascular invasion
or histological type of tumour.
In order to assess the specificity of loss of the Harvey ras
allele we have examined up to 5 other loci on the short arm
of chromosome 11, comparing tumour DNA with lympho-
blastoid cell line DNA from the same patient, as detailed in
Table III.
Heterozygosity was found on a total of 49 occasions and
the corresponding tumours had lost an allele in 19 cases
(38.8%). Nineteen tumour/cell line pairs have been fully
characterised for all 5 loci and allelic loss at one or more has
been found in 10 (53%).
We have also studied one informative locus (pepsinogen)
on the long arm of chromosome 11 and three at other
chromosomal sites (5q, 6p and 17q). Of 67 instances where
the patient was constitutionally heterozygous allele loss in
the tumour was found outside of the 1 lp region on only one
occasion (Table IV).
Discussion
These results, in agreement with several published studies
(Krontiris et al., 1985; Heighway et al., 1986; Thein et al.,
1986; Ceccherini-Nelli et al., 1987; Gerhard et al., 1987)
demonstrate that rare Ha-ras alleles can be identified in the
normal population. We have found no evidence for an
increased frequency of rare alleles in breast cancer patients,
contradicting both Krontiris' initial report (Krontiris et al.,
1985) and the findings of a subsequent larger series
(Lidereau et al., 1986) in which rare alleles were identified in
41% of breast cancer patients. Heighway et al. (1986)
reported a preponderance of the A4 allele in patients with
non-small-cell lung carcinoma, but several other studies have
failed to find evidence of linkage in myelodysplasia (Thein et
ai, 1986), colorectal adenocarcinoma (Hayward et al., 1988)
or familial melanoma (Gerhard, 1987). Lidereau's study on
breast cancer patients was performed on breast tumour
material which had been stored for up to 7 years, while the
controls were fresh blood samples from unaffected indiv¬
iduals. Wyllie et al. (1988) has suggested that prolonged
storage could lead to the identification of spurious 'rare'
alleles, and we have therefore used DNA from white blood
cells or lymphoblastoid cell lines, as well as tumour material.
In contrast to these negative findings, the observation that
a substantial proportion of breast cancers have lost one c-
Ha-ras allele confirms the recent report of Theillet et al.
(1986) and lends some support to the hypothesis that the
Ha-ras locus may be involved in breast cancer, albeit on a
rather different theoretical basis.
Knudson's 'two hit' hypothesis (Knudson, 1971) provides
a link between the molecular mechanisms underlying familial
and sporadic forms of the same type of cancer. In sporadic
cancer, a cell undergoes a somatic mutation, which must
then be followed by a second event to express the malignant
phenotype, either a second somatic mutation or loss of the
unmulated allele by non-disjunction or deletion.
Following the localisation of the retinoblastoma gene to
13q 14 (Cavenee et al., 1983) comparable deletions at other
sites have been reported in a variety of tumours, including
Wilms' tumour (Koufos et al., 1985), lung cancer (Kok et
al., 1987) and acoustic ncuroma/meningioma (Seizinger et
al., 1986).
The present findings raise the question 'Is the reduction to
homozygosity of the Harvey ras gene in breast cancer merely
an indication that there has been a deletion somewhere on
chromosome 11 and is there another gene in the region
much more directly involved in the disease?' Ali and collea¬
gues (1987) recently reported a total of 14 allele losses,
distributed between five polymorphic loci on lip in breast
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Table II Relationship between loss of a c-Ha-ras allele and oestrogen receptor
level in 61 breast tumours
ER poorl-ve ER moderate/rich
<20fmo!mg~1 protein >20fmolmg_1 protein (20)
Allelic loss 8 6
No allelic loss 10 37
40 r
P= <0.02.
No. Loss n = 51
Unknown - 10%
p = 0.04
0-9 20-29 40-49 60-69 8(
10-19 30-39 50-59 70-79
Tumour size in m.m.
90-99
Figure 3 Distribution of primary tumour size (greatest diameter
mm) in relation to Ha-ra.s allele status.
cancers from 9 patients, not all of whom were analysed for
every locus. We find reduction to hemizygosity of several
sequences other than Harvey ras on the same chromosome
arm, at least one locus being involved in 10 of 19 tumours
(53%), a frequency even higher than the corresponding
figure for Ha-ras (21.5%) and certainly much higher than
for informative loci outside lip (I of 67 informative loci, in
27 breast tumours). It might be unwise to extrapolate from
the present data, for example, to suggest that 11 p deletions
can be inferred in almost 50% of primary breast cancers
since only 19 tumours have been analysed in detail so far
and they include 8 already known to have lost a Ha-ras
allele. Nevertheless there has clearly been a substantial
frequency of DNA lesions within the short arm of chromo¬
some 11 in our tumour material. The simplest interpretation
is that a single mitotic recombination event has caused loss
of all loci distal to the breakpoint which, in some instances,
must have been on the centromeric side of the most proxi¬
mal sequence examined, P11F9, at 11 p 13. At least three of
the tumours studied, however, show patterns of allele loss
incompatible with this simple mechanism since one or more
loci on the telomeric side of the region of hemizygotisation
remain heterozygous and in one case (No. 8, Table III) there
were two regions of hemizygotisation separated by a locus
that remains heterozygous. It is necessary, therefore, to
invoke either multiple mitotic recombination events, localised
chromosome deletions, partial inversions or even more com¬
plex rearrangements. More extensive mapping studies are
required to resolve the issues raised by these observations
and analysis is now being extended to cover all one hundred
tumours in our series. One objective is to identify the
smallest region of chromosome lip that is consistently
included in any deletion that can be mapped. Such a region
Table III Details of allelic losses on lip in breast tumour DNA
compared with corresponding lymphoid cell line DNA
Tumour/
cell line Ha- ras jl-globin PTH Calcit FSH-ll P11F9
pair *1 *2 *3 *4 *5,6 *7,8
1 a— u a — a — a — a —
2 a — a — u u a — u
3 a — u u a — u u
4 a — u u ab ab u
5 a— u u u u ab
6 a — u u u u ab
7 a — ab u u u ab
8 a — ab a — u a — ab
9 ab u u u u a—
10 ab u u u u ab
11 ab ab ab u u ab
12 ab ab ab u u ab
13 u ab u u ab a —
14 u ab a — u u a —
15 u u a — u u a —
16 u ab u u u ab
17 u u ab u ab u
18 u a — u u u ab
19 u a— u u u ab
Centromere
15.5 15.4 15.3 15.1
ab = informative, not lost; u = uninformative; a—= allele loss,
'a' and 'b' should not be taken to refer to specific alleles.
*l=Shih & Weinberg (1982); *2 = Deisseroth et al. (1978);
*3 =Naylor et al. (1982); *4 = Hoppener et al. (1984); *5,6 = Glaser
et al. (1985), Watkins et al. (1985); *7,8 = Porteous et al. (1987),
Boyd et al. (submitted).
might then be the site of a putative tumour suppressor gene
(Friend et al., 1988).
This of course does not preclude the specific involvement
of other regions of the genome not examined in the present
study and it is quite possible that two or more putative anti-
oncogenes are involved in breast cancer (Lancet editorial,
1988). It is relevant to note that loss of heterozygosity has
been reported on I3q in 6 out of 10 ductal breast cancers
(Lundberg et al., 1987).
We find that loss of a Ha-ras allele correlates with paucity
of oestrogen receptor protein and with larger tumour size at
presentation, but there is no correlation between patho¬
logical lymph node involvement and loss of a Ha-rai allele.
Theillet et al. (1986) concluded that Ha-ras allelic loss was
significantly linked to parameters of tumour aggressiveness
since, in their material there were correlations between allelic
loss and paucity of oestrogen receptor protein, histological
grade and early occurrence of distant metastasis.
Table IV
Gene or No. No. No
probe Designation Localisation Restriction enz Ref* examined informative lost
Pepsinogen pH PEP I lq 12 EcoR 1 1,2 24 20 0
Erb A, pHcA2 17q 21.3 Bam HI 3 20 11 0
MIIC Class 11 pll-B-4 6p 21.3 EcoR 1 4 21 21 0
;.MS8 D8 S43 5q34qter Hin F1 5,6 18 15 1
Total 67 1
°l,2 = Taggart et al. (1985; 1987); 3 =Gosden et al. (1986); 4 = Gustafsson el al. (1984): 5,6^5inlomon et al. (1987), Wong
et ul. (1987).
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Of the six breast tumours identified in this series as
uninformative or heterozygous for c-Ha-ras, but showing
loss of an allele at one or more loci elsewhere on 11 p (cases
9, 13, 14, 15, 18 and 19, Table III), five had low or absent
oestrogen receptor. The correlation between this prognostic
feature and hemizygotisation of sequences somewhere on 1 Ip
therefore does not seem to be exclusive to the Harvey-rax
locus. Although such a conclusion must be tentative until a
larger number of tumours has been analysed in similar
detail, the suggestion is that c-Ha-rax serves as a relatively
inefficient index of hemizygotisation of a specific locus some
distance away.
It will be of great importance to map that putative locus
and thereafter to reassess the clinico-pathological correla¬
tions already established, to see if information of prognostic
value can be obtained from DNA analysis of tumours at
presentation. The clinical relevance of such findings will be
established by follow up of our patient cohort to gather data
on disease-free interval and long-term survival. Ultimately
the objective is to define the gene itself and to establish the
mechanism whereby it contributes to the evolution of breast
cancer.
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Risk Factors in General
In common with many neoplasms, the incidence of breast cancer increases with age
[24], It is slightly higher in socioeconomic classes I and II [52] and in North
American and European women compared with African and Asian women [127].
The behaviour of the ovary appears to play a central role in the aetiology of breast
cancer; several studies showing that early age ofmenarche (below 14 years) and late
age of menopause, increase the risk [20, 107, 12, 119]. The effects of pregnancy are
less clear; childbearing appears protective if the first child is born before the mother
reaches the age of 30, although bearing more than five children increases the risk
[12, 26, 125, 76, 1]. Alterations of the hormonal environment, as in prolonged use of
oral contraceptives or postmenopausal oestrogens, do not appear to affect the risk
in most recent studies, but this remains a controversial issue [12, 51, 122, 123, 124,
98, 78]. Artificial menopause, for example by oophorectomy, is reported to be
protective; the earlier it is performed the greater the reduction in risk [69, 33].
Past medical history is of particular importance in the assessment of risk. A
previous diagnosis of cancer in one breast significantly increases the likelihood of
developing a second primary tumour in the other [66, 110], Many studies have
suggested that a history of benign breast disease, particularly if a biopsy was
performed, increases risk [25, 77, 48] although this has been disputed [12, 18] and
certainly the pathological findings in the biopsy are not predictive [78], A history of
primary cancer in the ovary or endometrium has also been reported to increase the
chance of subsequent breast cancer [75, 92],
Many other factors, such as body mass, have been shown to be related to very
small increases in risk [65, 61], but the strongest predictive factor so far identified
and the one which we will now examine in more detail, is a positive family history of
breast cancer.
Family History
The occurrence of families containing a large number of individuals affected by
breast cancer has been recognised for many centuries. The first detailed report was
published in 1866 by the Flench surgeon Paul Broca [13] who ascertained the
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cause of death in 38 individuals through five generations of his wife's family. Of the
24 women in that family, 10 died of breast cancer and several more individuals died
from other malignancies. Both Broca and his contemporary Sir James Paget
[84, 63] expressed concern that multiple instances of such a common disease might
appear in a small number of families by coincidence, but, using the available data on
cancer mortality rates in the normal population, they concluded that a tendency to
•develop breast cancer could indeed be inherited.
Advances in statistics, epidemiology and genetics allowed more rigorous
examination of these initial observations in the first half of the twentieth century.
Several groups attempted to compare the mortality from breast cancer in
a population of patients with one or more affected relatives and in a normal control
population [49, 132, 4, 52, 70]. These studies highlighted the importance of
pathological verification of malignancy, of assessing the incidence of malignancies
other than breast cancer and of using large numbers of families plus reliable data on
cancer incidence and mortality in the general population. Overall, they showed that
there was a twofold increase in breast cancer incidence in the close female relatives
of breast cancer patients. Underreporting of disease by control subjects was
recognised as a significant problem which remains hard to surmount. Further
analysis of data collected in the course of these studies hinted at the possibility of
there being two separate types of breast cancer, sporadic and hereditary, and
suggested that several features were commoner in one type than the other.
The important characteristics of familial breast cancer in a number of countries
have been defined by H.T. Lynch and colleagues [71]:
1. Significantly early age of onset
2. Excess of bilaterality
3. Excess of multiple primaries at various sites
4. Vertical transmission (mother to daughter)
5. Impaired survival when compared with sporadic forms. Applying these criteria,
he estimates that 5% of all breast cancer is familial, but 11.5% of patients with
breast cancer diagnosed before the age of 50 have a familial form of the disease.
Anderson [5, 6] adopted a somewhat different approach, dividing his cases into
subgroups and identifying the groups in which the risk was increased beyond the
two- or threefold level observed in the earlier studies. The relative risk to first-degree
female relatives of patients with premenopausal breast cancer was 3.1, while no
increase in risk was observed among relatives of postmenopausal patients. If the
patient had bilateral breast cancer the risk to first-degree female relatives was
increased fivefold. If both conditions applied (i.e. the patient was premenopausal
and had bilateral disease), the risk to first-degree relatives was increased ninefold.
Furthermore, the relatives of patients with bilateral disease were at a ninefold times
greater risk of developing bilateral disease themselves as compared with relatives of
patients with unilateral disease.
The importance of age and of bilaterality have been confirmed in other studies
[7, 17] and so, despite one dissenting report from a large Swedish study in which the
effects of family history, age of onset and bilaterality were rather weak [2], we are
now in a position to identify a group of women who are at significantly higher risk
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of developing breast cancer than the general population, who are likely to be more
aware of (and concerned about) their susceptibility to the disease [50], and who
therefore require detailed and accurate counselling about that risk [83]. By
combining complex statistical analyses and laboratory investigation it is possible to
define more precisely the genetic component in what is acknowledged to be a
disease of multifactorial aetiology.
Segregation Analysis
In some "classical" genetic disorders, inspection of the pedigrees of a few affected
families will reveal the mode of transmission (autosomal or sex-linked, dominant or
recessive). However, in the vast majority of disease, where the genetic component is
less clear cut, a more comprehensive statistical analysis is required. Segregation
analysis is the name given to the process of determining the probable mode of
transmission of a trait, from an observed distribution of phenotypes in a pedigree or
a number of pedigrees.
The procedure involves calculating how well the observed distribution of
phenotypes fits various hypotheses and can thus establish the validity of some of
these hypotheses, though it may not prove conclusively that a trait is transmitted
genetically. The larger the families examined, the more affected individuals in each
family; the larger the total number of families, the better will be the data and the
more secure the final conclusions.
Several statistical advances, such as maximum likelihood scoring, the concept of
multifactorial inheritance, the "mixed model" and a sampling correction to allow
for the manner in which the pedigrees have been ascertained and relatives added
[29, 30, 80, 27, 60, 81], have all been incorporated into a segregation analysis
performed on 200 Danish families with breast cancer [131].
The observed distribution of breast cancer in these families was compatible with
transmission of a single autosomal gene with dominant expression, the frequency of
the abnormal (disease) allele being 0.7%, and the penetrance varying with age.
According to that model, by age 80, a female heterozygous for the abnormal allele
would have a 57% chance of developing breast cancer. For cancers presenting
before age 30, 88% of affected females would be carriers of the disease gene whereas
for the total population (presentation up to age 80), only 13% of affected females
would carry the gene, the other 87% having developed "sporadic" breast cancer.
Several similar analyses have been performed on another large family with
breast cancer and all agree that an autosomal dominant gene with incomplete
penetrance is the most likely mode of transmission [35, 44, 36]. Increasing the
complexity of a segregation analysis may well improve the accuracy of estimates of
gene frequency and penetrance, but it cannot give any indication as to what gene is
involved and where in the human genome it may be.
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The Principles of Linkage Analysis
The most practical approach to locating the gene for susceptibility to breast cancer
is by the technique of linkage analysis, based on the segregation of defined genetic
markers in affected and unaffected family members [133]. The human genome is
composed of genes arranged in a linear fashion along the 23 pairs of chromosomes.
Genes which are close together on the same chromosome tend to be transmitted
together, i.e. to segregate nonindependently. Genes on different chromosomes
segregate independently so that every possible combination of alleles appears with
equal frequency in the gametes, as illustrated by Fig. 1. The disease gene is
D (normal allele d) and the marker gene alleles are represented by T and r.
If the disease gene and the marker gene are physically very close together, they
will be transmitted together, so that the gametes formed are either DT or dt as
shown in Fig. 2. This departure from independent segregation is termed "linkage",
with D and T being very tightly linked in the example shown. If D and Tare slightly
further apart on the chromosome, the two genes may well be transmitted together,
but because they can segregate by crossing over and recombination at meiosis, a few
^ gametes with genotypes Dt or dTwill appear, as illustrated in Fig. 3. These gametes
are known as recombinants and the proportion of recombinant gametes in the total
pool is the recombination fraction. The further apart the two genes are, the more
likely it is that recombination will occur, until eventually the two genes will appear
to be segregating independently as all four possible genotypes will be represented
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Fig. 1. Independent assortment of alleles at meiosis for a disease locus (alleles D and d) and a
marker locus (alleles T and t) on different chromosomes. (After [133])






. Fig. 2. Absence of independent assortment of
alleles at meiosis for disease and marker loci
very close together on the same chromosome
(tight linkage). (After [133])
The markers used in linkage analysis must be polymorphic (i.e. more than one
allelic form found in the population), and ideally the chromosomal location should
be known. After identifying which allelic forms of the marker are present in every
individual (both affected and unaffected) in a family, it is possible to calculate a the
probability of the observed distribution occurring by chance if there is no linkage
between the marker gene and the disease, and b the probabilities of such a pattern
appearing if there is linkage at different recombination fractions. The logarithm of
b/a, known as the "lod" (logarithm of odds) score, is calculated for various
recombination fractions [79]. To attain statistical significance it is usually necessary
to combine data from several families, and the lod scores from each family for each
recombination fraction can be added together. A lod score greater than +3 is
usually taken as demonstrating significant linkage, but obviously the more families
examined, the greater the confidence one can place in the lod score.
King, Go and colleagues [53, 38] used segregation analysis to identify ten
families showing genetic transmission of the breast cancer trait and performed
linkage analysis with 21 independent polymorphic markers. They suggested that in
seven families there was insignificant linkage between an autosomal dominant gene
for susceptibility to breast cancer and the enzyme glutamate-pyruvate transaminase
(GPT), the gene which is located on chromosome 16 [73]. They reported a lod score
of + 1.95, at a recombination fraction of zero and accepted that such a result should
be viewed with caution. When a larger number of families was examined, it was
conclusively shown that there was no linkage between GPT and susceptibility to
breast cancer [74],
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Fig. 3. Disease and marker loci
nearby on the same chromosome
showing linkage. The recombina¬























Fig. 4. Disease and marker loci
far apart on the same chromo¬
some mimic independent assort¬
ment and linkage cannot be de¬
tected. The recombination frac¬
tion is 50%. (After [133])
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Confusion sometimes arises between the terms " linkage" and "association" in
the context of genetics. As explained, linkage between two DNA sequences means
that they are physically close together in the genome. Hence if one is polymorphic,
so that inheritance of the different alleles can be traced within a family, it can be
used to "tag" the other sequence. It does not follow that the same allelic forms of the
two sequences are linked in all cases. For example, in the case illustrated in Fig. 2 a
single chromosome carried D and T in tight linkage so that T would serve as a
marker for D in this family. In another family, however, the relevant chromosome
might carry the alleles D and t in which case the marker for D would be t. In other
words, there is no functional relationship between the gene with alleles Dd and that
with alleles Tt. The important practical consequence is that even if strong linkage is
established between these genes, there is no purpose in screening a population, say
for carriers of the t allele, since one could not predict which of the individuals so
identified would also carry D. That type of prediction is valid only within each
family.
"Association", however, is quite a different matter. The term implies that
particular allele of a given gene is overrepeated among the total population of
patients with a particular genetic disorder. There are, for example, over 100 diseases
associated with individual alleles of the major histocompatibility system [118].
HLA-B27 and ankylosing spondylitis, or DR4 and rheumatoid arthritis are well-
known instances. These associations hold across family boundaries (though,
interestingly, they may not apply in all racial groups) and can therefore be useful in
population screening. Association in this sense may come about because the disease
arose through a single mutation event affecting a gene so close to the "marker"
sequence that the disease and marker alleles have never become separated
throughout the succeeding generations. This so-called founder effect implies that
all the affected individuals in a population are actually related through they may
not be aware of it. An equally likely mechanism, however, is a causal relationship
between the marker allele and the disease itself. In other words, individuals with
the HLA type B27 are at risk from ankylosing spondylitis not because an "ank-
spond" gene lies close to the HLA complex on the short arm of chromosome 6,
but because the B27 gene product is actually involved in the aetiology of the
disease.
Returning to the problem of genetic susceptibility to breast cancer, the search
for linkage, in the strict sense, simply means extension of the approach used by
King, Go and their colleagues, namely the analysis of large numbers of randomly
chosen polymorphic markers in families with multiple cases of premenopausal
disease. An alternative approach would be to try to identify "candidate" genes
suspected, for one reason or another, of possible involvement in breast cancer.
The gene encoding the oestrogen receptor might be an obvious choice as
would a number of oncogenes (see later). Until recently, the shortage of
useful genetic polymorphisms has restricted both of these approaches, but the
situation has been transformed by the discovery of DNA restriction fragment
length poymorphisms and other advances in molecular biology discussed in the
next section.
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Basic Molecular Biology
The total human gene complement is stored and transmitted in the form of
deoxyribonucleic acid. DNA is a double-stranded helix. Each strand is composed of
a string of sugar and phosphate molecules forming the backbone, with a series of
bases protruding. In DNA there are four possible bases, adenine, guanine,
thymidine and cytosine, and in native double-stranded DNA, A must be opposite T,
and G opposite C. The genetic information coded by the order of bases in the DNA
is transcribed into RNA, and RNA is then translated into protein. Because of the
requirements for complementary base pairing (A-T and G-C) a single strand of
•
) DNA uniquely defines its complementary strand of DNA or RNA.
Under appropriate conditions of pH, temperature and ionic strength, single-
stranded DNA or RNA fragments will stick to (or "hybridise" with) complementary
single strands of DNA. The stability of the double-stranded complex ("hybrid")
depends upon the degree of complementarity between the two nucleic acid strands.
By increasing the pH or temperature or altering the ionic strength, hybridisation
conditions can be made more stringent until only strands that are perfectly matched
at every base pair will remain as hybrids. This property is exploited in the technique
of gene probing.
DNA is extracted from cells by well-defined chemical procedures involving
phenol extraction and ethanol precipitation, stripped of contaminating RNA and
protein and then must be cleaved into fragments of manageable size. This is most
conveniently achieved by digestion with restriction enzymes, large numbers of
which have becpme commercially available over the past 10 years. Each of these
enzymes, isolated from bacteria and fungi, recognises a specific base sequence in
double-stranded DNA and cuts strands at that point [94].
The fragments thus produced can be separated by electrophoresis in an agarose
gel. The shorter fragments will move faster through the gel and so will travel further
away from the origin in a given time than large heavier fragments [108].
It is much easier to work with DNA on a solid support than in a gel and
therefore the DNA is transferred onto either nitrocellulose paper or a nylon
membrane by a method first described by Dr. E.M. Southern [106]. This maintains
the spatial relationship between the DNA fragments generated by the gel electro¬
phoresis. After "denaturing" the DNA with NaOH, to separate the two strands, the
gel is placed on a piece of filter paper, supported by a glass plate, with both ends
dipping into a concentrated salt solution. The membrane is placed on top of the gel
and pressed down onto it with a heavy weight. The salt moves down its
concentration gradient, carrying the DNA from the gel to the membrane, and the
weight assists by gradually compressing the gel, forcing the DNA out. After this
overnight "blotting" procedure, the membrane is exposed to ultraviolet light for
2-5 min. This links the single-stranded DNA to the membrane by covalent bonds. A
similar blotting technique can also be applied to RNA transfer [117].
The next step is to create a labelled DNA or RNA probe (i.e. millions of identical
copies of a particular base sequence). The probes themselves are obtained by
cloning the required piece of DNA as an insert in a virus-like vector which will grow
in a bacterial host, usually Escherichia coli. The commonest method of labelling a
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DNA probe is "nick translation" [93]; a segment of double-stranded DNA is
incubated with a mixture of three unlabelled nucleotides plus one nucleotide
containing radioactive 32P atoms. The enzymes DNAse and DNA polymerase I are
added. The DNAse introduces breaks ("nicks") at random in one DNA strand and
the DNA polymerase moves along that strand cutting out nucleotides and then
replacing them, using the other strand as a template. In the course of this repair
phase, 32P-labelled nucleotides are introduced into the DNA. Other methods have
been used to label DNA and RNA probes to a higher specific activity with 32P and
the use of nonradioactive labels has also been explored [45].
The membrane, bearing the imprint of the original DNA gel fragments, is
immersed in a complex hybridisation solution containing the labelled probe,
\ \ shaken overnight at 68°C and then washed to remove unhybridised probe. If
^ stringent washing conditions are used, the probe will hybridise only to those
- \ fragments of DNA on the filter to which it is exactly complementary. After
autoradiographic exposure (1-10 days at — 70°C), one or more discrete bands
appear on the film. These bands correspond to the DNA fragments ori the
^' membrane to which the probe has hybridised and the size of these fragments can be
determined from the positions of the bands (Fig. 5).
At least 90% of the DNA in a human cell does not encode any protein product,
i.e. does not consist of "genes". While this material is not necessarily devoid of
function, it is evidently much more tolerant of variation in base sequence than the
genes themselves. Hence, within the species there is much more polymorphism of
the nontranslated DNA than of the genes. One aspect of this polymorphism is the
gain or loss of restriction enzyme cleavage sites, the positions of which can vary
considerably from one individual to another. Thus, when DNA is cleaved with a
restriction enzyme and the Southern blot probed with a particular labelled
sequence, the size of fragment bearing the complementary sequence is quite likely to
show some variation within the population. This "restriction fragment length
polymorphism" (RFLP) provides an enormous pool of genetic markers since
the positions of restriction sites are still sufficiently stable for the DNA fragment
lengths to behave as alleles obeying the simple laws of Mendelian inheritance.
"Anonymous" DNA probes recognising sequences that are not necessarily parts of
structural genes, now represent a major resource in human gene mapping and
genetic analysis. They may be used simply to increase the pool of "random"
polymorphisms for the conventional "shotgun" approach to linkage studies or they
may serve to provide polymorphic markers for adjacent candidate genes. The latter
application, ironically, tends to blur the distinction just made (at some length!)
between "linkage" and "association" for the candidate gene and by definition, will
be causally related to the disorder (implying "association"). Nevertheless, when the
allelic forms of that gene are identified on the basis of RFLP rather than by the
putative mutation directly responsible for the disease, then any observed correla¬
tion between a particular allele and disease susceptibility will apply only within an
individual family, i.e. we are dealing with true "linkage". Of course, in such an event,
the logical course would be to analyse the implicated gene in sufficient detail to
permit direct identification of the crucial DNA lesion which would, in turn, provide
a basis for population (as distinct from family-based) screening.
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Fig. 5. Southern blotting. [108]
An Outline of Oncogenes
Identification of genes likely to be of importance in the aetiology of human cance
has resulted from three main experimental approaches: investigation of turnout
producing viruses; transfection of human tumourigenic DNA into immortalised ce;
lines; and direct comparisons of malignant and nonmalignant tissue at th
molecular level.
The first clues came from an understanding of the structures of oncogeni
retroviruses. The genetic material of these viruses is RNA, but once inside a
infected cell, the RNA is copied into DNA which then integrates into th
chromosomal DNA of the host. Later it may be transcribed and translated by th
host cell's replication system, unleashing a second generation of virus. The viruse
can be divided into two broad groups, depending on the rapidity with which the
produce tumours. Slowly transforming viruses contain three genes; gag which code
for specific antigens mainly located at the core of the virus, pol, which codes fo
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reverse transcriptase and env, which codes for the envelope protein. The acutely
transforming viruses contain another gene, termed an "oncogene", specific to each
virus and directly responsible for induction of malignancy in infected cells [10].
Analysis of the nucleotide sequences of retroviral oncogenes revealed that they
were very similar to sequences (proto-oncogenes) found in the genome of higher
organisms, including humans [109, 8], It is virtually certain that the acutely
transforming viruses arose by recombination between nononcogenic or slowly
transforming viruses and the cellular proto-oncogenes. At least 22 viral oncogenes
have been identified so far [9].
The second productive experimental approach has been direct DNA trans-
fection/transformation. DNA from human tumours or tumour cell lines is pre¬
cipitated onto the surface of cells in culture by calcium phosphate. A small
proportion of the DNA enters the cells and an even smaller fraction becomes
integrated into the genome in a random fashion. Cells "transformed" by this
technique exhibit uncontrolled proliferation and form distinct colonies, which can
be isolated and cloned up [103]. When injected into immunologically compromised
animals, such as nude or neonatally thymectomised and irradiated mice, these
transformed cells produce tumours, suggesting that a segment of DNA responsible
for producing the original human tumour, has been integrated into the cell's
genome [58, 86]. These oncogenes can then be identified by comparing extracted
DNA from the transformed cells and from the original cell line.
Eleven new cellular oncogenes, without viral counterparts, have been identified
by this technique [9]. Among the few oncogenes identified by both transfection and
viral studies are members of the ras gene family which will be considered more fully
in the next section.
One of the main limitation of DNA transfection studies is that the target cells
used, usually 3T3 or CI27 mouse fibroblasts, though subject to some normal
growth controls, are immortal. They therefore represent an intermediate stage
between the normal and full-blown malignant states. Cotransfection of at least two
different oncogenes, for example, Ha-rus and c-myc, is generally required to achieve
tumourigenic transformation of normal cells [62]. This observation strengthens the
theory that carcinogenesis is a multistage process, but raises the question of what
changes have already taken place in immortal cell lines commonly used as targets
for transfection assays and hence what (restricted) range of new oncogenic events
they may be capable of detecting.
Chromosome Analysis
The alterations in genetic material that are required to induce malignant change are
far beyond the limits of resolution by direct visualisation of stained chromosomes.
Nevertheless, they may come about in the course of major (visible) structural
rearrangements. The easiest neoplastic cells to examine in this fashion come from
haematological malignancies. Several well-defined chromosomal abnormalities
have been found consistently in various types of leukaemia and lymphoma [97]. By
concentrating on regions of the genome involved in specific chromosome aberr-
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ations, molecular biologists have identified three novel oncogenes [43, 120, 121]
and have achieved greater understanding of the mechanisms involved in cellular
oncogne activation. It is much harder to obtain good chromosome preparations
from solid tumours, but some progress has been made. There are, for example,
reports of recurring deletions in the short arm of chromosome 3 in small cell lung
cancer and in renal carcinoma [128, 134]. The possibility of localising a genetic
lesion in breast cancer by a similar approach is therefore not to be discounted.
By combining the three experimental approaches already outlined, around 40
DNA sequences in the human genome have been classed as proto-oncogenes [9],
These proto-oncogenes may be activated to become oncogenic by changes either in
their structure or in regulatory elements. A specific alteration in the nucleotide
sequence (a point mutation) activates the ras gene family, resulting in the produc¬
tion of an abnormal protein product [90]. In chronic myeloid leukaemia, trans¬
location between portions of chromosomes 9 and 22 results in the juxtaposition of
two oncogenes, leading to the production of a hybrid mRNA and a hybrid protein
product [43], Translocation of another oncogene, c-myc, from chromosome 8 to
chromosome 14 in Burkitt's lymphoma results in dysregulation ofc-mfyc, leading to
a continued expression of the normal gene [54, 64, 113], which is usually as the cell
differentiates [22, 40]. Overproduction of a normal protein product can also result
from an increase in the copy number of an oncogene [102],
Harvey ras
In the context of breast and other human cancers, one of the most intensively
studied oncogenes is Harvey ras (c-Ha-ras). The proto-oncogene was first identified
as the sequence which, on transfection from a human bladder cancer cell line, was
capable of transforming mouse 3T3 fibroblasts into tumourigenic cells [103,39]. Its
similarity to the ras oncogene of the Harvey rat sarcoma virus was quickly
established and the human gene has been mapped to the short arm of chromosome
11 [72]. Analysis of the nucleotide sequence has shown that the Harvey ras proto-
oncogene becomes tumourigenic by a point mutation in either the 12th or the 61st
codon [90, 100]. There are two other closely related proto-oncogenes: Kirsten ras
(K-rus) on chromosome 12 and N-ras on chromosome 1, coding for almost identical
proteins of 189 amino acids, known as p21 [14, 112]. By analysis of DNA fragments
on Southern blots, alterations involving ras sequences have been identified in about
10% of the commonest forms of human solid tumours [88] and in up to 80% of
chemically induced rat mammary tumours [111], A Harvey ras gene mutuation has
also been found in a cell line derived from a carcinosarcoma of the breast, but not in
normal breast cells of the same patient [57],
Abnormally high levels of the normal protein p21, induced by increasing the
rate of transcription or the number of copies of the normal Harvey ras proto-
oncogene, will transfrom 3T3 cells in culture [85, 89], Primary human breast
tumours have significantly higher levels of p21 than normal mammary tissue
[46, 82, 129] and alterations in structure or regulation of the Harvey ras gene are of
importance in the aetiology or progression of breat cancer.
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Near the Harvey ras gene lies an untranslated region made up of a variable
number of repeated DNA subunits [14]. Digestion with the restriction enzyme Bam
HI generates a fragment bearing Ha-ras plus the untranslated subunits. Since they
vary in number, the fragment length is variable, i.e. this is an example of RFLP.
There are four common alleles in the normal population, (named Alt A2, A3, A+)
and a number of very n^uch rarer alleles. In 1985 Krontiris et al. [59] reported that
among patients with a variety of solid or haematopoietic malgnacies there were
significantly more rare alleles than in a control population. Since the alleles can be
identified in any tissue, including white blood cells, if this report could be confirmed
it would offer a real possibility of identifying a blood-borne marker for high risk of
developing cancer.
Furthermore, it suggests that information about a gene involved in familial
breast cancer might be obtained from direct analysis of a large series of unselected
tumours, rather than concentrating only on patients with multiple affected first-
degree relatives, bilateral disease and early age of onset. Though this may seem
paradoxical, there are precedents which may prove to be highly relevant. The
hereditary form of retinoblastoma is associated with an inherited deletion of part of
chromosome 13 and there is evidence that the same region of the genome has
become abnormal in tumour tissue from sporadic (i.e. nonhereditary) cases [16].
More recently, the gene for familial adenomatous polyposis (an autosomal domi¬
nant condition leading to multiple colon cancers if not treated by early colectomy)
has been mapped to the long arm of chromosome 5 and a lesion of the same
chromosome arm has been recognised in tumour material from a substantial
proportion of sporadic large bowel cancers [11, 105],
Harvey ras Alleles in Primary Breast Cancer
The differences in restriction fragment length for the four common Harvey ras
alleles are considerable and it is therefore relatively simple to separate them. Rare
alleles however, tend to be much closer in size to their common counterparts. This is
illustrated by the autoradiograph in Fig. 6.
We have determined the frequency of the different Ha-ras Bam HI restriction
fragments in tumour tissue from a series of 100 female patients with breast cancer
prior to treatment in the Department of Clinical Surgery, Edinburgh University
Medical School, and in 100 placentae (to act as a control panel representative of the
local Edinburgh population). Table 1 shows the relative frequencies of the alleles in
these two groups.
There is no significant difference between breast cancer patients and controls in
respect of any alleles (rare or common). This large series therefore contradicts the
findings of Krontiris and the subsequent report from Lidereau and colleagues [68]
which related specifically to breast cancer. Negative findings, however, have
emerged from similar studies in myelodysplasia [115], lung cancer [47] and
melanoma [37].
In the course of this study we noted that in several of the heterozygous tumours
the autoradiographic band representing one allele was darker than the other








Fig. 6. Alleles of c-Ha-ras (Bam HI digests). The left-hand track of this Southern bk
contains a "doublet" of allele A, and the rare variant A\
Table 1. Relative frequencies of Harvey ras alleles




Number (%) Number (%)
122 61 135 67.5
A2 26 13 27 13.5
A, 26 13 19 9.5
21 10.5 15 7.5
A\ 5 2.5 4 2.0
200 200
(Fig. 7). A possible explanation is that the tumour cells have lost one allele and th
fainter band results from contamination of the tumour sample by normal whit
blood cells. This interpretation was supported by comparing tumour DNA an
white blood cell DNA from the same patient (Fig. 8). Since a tumour with minim;
white blood cell infiltration might appear homozygous, we have examined whit
blood cell DNA from most of the patients with apparently homozygous turnout
and have identified four who are constitutionally heterozygous. The current state
of this investigation is set out in Table 2. The 100 tumours therefore fall into thre
groups: (a) 52 with no allele loss; (b) 13 with loss of one allele; and (c) 35 which awa
definition, of which 27 are constitutionally homozygous.
As seen in Table 3, loss of Harvey ras allele is significantly correlated (P <0.0.'
with poverty of oestrogen receptor protein, which is known to indicate a poc
prognosis [21, 78, 130],
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Table 2. Restriction fragment length polymorphisms (RFLP) in DNA form
breast Tumours and white blood cells (WBC)
100 Tumours characterised for Harvey ras alleles
61 Hererozygous 39 Apparently homozygous
9 Allelic bands of different density 31 WBC DNA examined
52 Allelic bands of equal density 4 Heterozygous
WBC DNA examined in 5 27 Homozygous
We are currently evaluating the correlation between allelic loss of Ha-rns and
other prognostic factors, such as tumour size, progesterone receptor levels and
axillary lymph node involvement [99], to clarify the suggestion that loss of a
Harvey ras allele is amarker for a more aggressive tumour behaviour [3, 114]. Loss
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Table 3. Loss of Harvey ras allele and poverty of oestrogen
receptor protein (ER)
ER-poor (22) ER-rich (43)
Allelic loss (13) 8 (61%) 5 (39%)
No allelic loss (52) 14 (27%) 38 (73%)
P <0.02.
of an allele may be caused by several different mechanisms, including non¬
disjunction (loss of a complete chromosome), alone or followed by reduplication of
the remaining chromosome [16].
Deletion of a portion of chromosome 11 has been reported in Wilms' tumour
[55, 31, 91], hepatoblastoma [56], hepatocellular carcinoma [96] and transitional
cell carcinoma of the bladder [32] although it has yet to be established whether
precisely the same region is involved in the different tumours. Cytogenetic analysis
of primary breast cancer has revealed no consistent loss of large portions of
chromosome 11 [95], but it remains possible that a submicroscopic deletion exists.
The next phase of the study will involve examination of other polymorphic genes
known to be on chromosome 11, as loss of one whole copy of the chromosome will
result in reduction of all these genes to homozygosity. This strategy could also
enable us to define the size of any deletion, as there may turn out to be a region of
chromosome 11 close to (but not including) the Harvey ras gene that is deleted in a
higher proportion of breast tumours, a feature likely to be of importance in the
aetiology of breast cancer. A change of chromosome 11, but not of the Harvey ras
gene, would be ironic since it would refute the logic underlying the choice of c-Ha-
ras as a candidate for a genetic marker of breast cancer susceptibility. Nevertheless
serendipity has its place in most research programmes and it is not to be despised.
A note of caution must be sounded when drawing conclusions from genetic
lesions found in tumour tissue. Biochemical and cytogenetic evidence has been
available for many years to show that malignant cells tend to accumulate multiple
aberrations in their DNA, including gene deletions [87, 99], It is unlikely that all -
or even many - of them contribute to the malignant state. Refinements in molecular
biology have confirmed and extended these findings [116]. It will therefore be
necessary to scan the rest of the genome of breast cancer cells before concluding that
a deletion in the vicinity of c-Ha-ras is significantly associated with the disease.
The Future
In addition to the Harvey ras gene, several other oncogenes have been studied in
primary breast cancer. The erb-B2 gene, mapping to the long arm of chromosome
17 [19, 34] codes for a protein similar to epidermal growth factor [101], and is
amplified in 30% of primary breast tumours. Amplification of this gene is a
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prediction of both disease-free interval and overall survival and has a greater
prognostic value than oestrogen receptor status [104].
Amplification of another oncogene, c-myc on chromosome 8 has been reported
in 30% of primary breast tumours [28], but this is not significantly linked to disease
progression. A rare restriction fragment bearing the c-mos locus (on chromosome 8)
has been identified in a small number of patients with breast cancer [67], but in the
absence of a formal linkage analysis, the significance of this finding remains unclear.
In addition to the known oncogenes, one of the genes likely to be of interest in
breast cancer is the recently cloned gene for the oestrogen receptor protein [42]. A
high level of oestrogen receptor protein in a breast tumour is a good prognostic sign
[130]. The gene coding for the oestrogen receptor protein maps to chromosome 6
[126,41] and there is extensive homology between it and the erb-A oncogene of the
avian erythroblastosis virus [23]. The identification of any rearrangement or
amplification of this gene in primary and metastatic breast cancer would be
important and the recent finding of an RFLP with the enzyme PVU II, [15] will
allow a linkage analysis of families with a high incidence of breast cancer.
In conclusion, it is clear that the techniques ofmolecular biology can contribute
to a better understanding of the aetiology and progression of breast cancer in two
ways. Identification of alterations in the genetic material that contribute to
progression from a normal breast epithelium cell to a malignant cell is fairly well
advanced. However, the search for a genetic marker for high risk of developing
breast cancer will gather momentum as more and more polymorphic DNA markers
become available. If successful, it will represent a major breakthrough in the
targeting of expensive screening techniques to those women who are most likely to
benefit.
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